

University of South Carolina Scholar Commons

Theses and Dissertations

2018

Enhancements in Alginate Microencapsulation Technology & Impacts on Cell Therapy Development

Marwa Belhaj

University of South Carolina

Follow this and additional works at: <https://scholarcommons.sc.edu/etd>



Part of the [Biomedical Commons](#)

Recommended Citation

Belhaj, M.(2018). *Enhancements in Alginate Microencapsulation Technology & Impacts on Cell Therapy Development*. (Doctoral dissertation). Retrieved from <https://scholarcommons.sc.edu/etd/4475>

This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.

ENHANCEMENTS IN ALGINATE MICROENCAPSULATION TECHNOLOGY & IMPACTS ON CELL THERAPY DEVELOPMENT

by

Marwa Belhaj

Bachelor in Pharmaceutical Sciences
Al-Fateh University, 2005

Master of Science
University of South Carolina, 2014

Submitted in Partial Fulfillment of the Requirements

For the Degree of Doctor of Philosophy in

Biomedical Science

School of Medicine

University of South Carolina

2018

Accepted by:

Jay Potts, Major Professor

Daping Fan, Committee Member

Wayne Carver, Committee Member

Gregorio Gomez, Committee Member

Richard Goodwin, Committee Member

Cheryl L. Addy, Vice Provost and Dean of the Graduate School

© Copyright by Marwa Belhaj, 2018

All Rights Reserved.

DEDICATION

To the memory of my father, Omar Belhaj (1937-2014), who would have been proud of me reaching my goals.

To my mother, Aziza Abo-Janah, for her constant, unconditional love, and support toward success.

To my dear husband, Suliman Arebi, who has been a constant source of support and encouragement during the challenges of graduate program and in daily life. I am truly thankful for having you in my life, and for helping me figuring out my path for bright future.

To my lovely boys, Zakaria and Isa, who were patient enough to postpone all of their fun plans in order for me to complete my mission. I love you more than anything and I appreciate all your patience and support during momma's Ph.D. studies.

ACKNOWLEDGEMENTS

Foremost, I would like to express my sincere gratitude to my advisor Dr. Jay Potts for the continuous support on my PhD's study and research, for his patience, motivation, and immense knowledge. I am really thankful for such an opportunity working in his lab, learning, and training for bright future in the research field. His guidance helped me in all the time of research and writing of this dissertation, and without his mentorship and guidance this is not possible.

Also, I would like to thank my committee members: Dr. Daping Fan, Dr. Wayne Carver, Dr. Gregorio Gomez, and Dr. Richard Goodwin for serving on my dissertation committee and for their encouragement, insightful comments, and continuous help.

I would like to acknowledge all of current and past members of Dr. Potts's lab for their support, help, and answering my continuous questions. My lab members including Vinal Menon, Ambrish Kumar, Chad Simmons, Weber Pike, and Edgar Macal.

My sincere thanks to the most important people who could be in my life, my family. Including my soulmate, Suliman, and my precious kids. This work would have been impossible without their hugs, love, and support.

To my friend, Fatma Saaoud, who was such a great friend with all of her helpful advices and precious friendship.

ABSTRACT

Biodegradable alginate microcapsules (MC) are recently becoming widely used in the biomedical field, and have shown effectiveness as a drug delivery system. Alginate has been used in microencapsulation due to its simple gelling process, biodegradability, excellent biocompatibility, and its stability under in-vivo conditions. Alginate polymer is a natural polysaccharide derived from brown seaweed and has the ability to polymerize rapidly in the presence of cations to form a porous matrix. In order to advance the previous system for efficient protein and peptide delivery, we further lyophilized the peptide-filled microcapsules and we were able to rehydrate, and test them for sustained release. Electrospray method, as a microencapsulation technique, has been previously used to encapsulate peptides and proteins successfully using alginate. A second coating of poly-l-ornithine (PLO) polymer can be used to increase the integrity of alginate microcapsules. Alpha-carboxy terminus 1 (α CT1) peptide, Human platelet lysate (HPL), and bovine serum albumin (BSA) were examples of peptides and proteins that were successfully encapsulated by our lab.

Cell-based therapies represent a revolutionary bio-technique that has been applied widely in medicine. Recently, they have been successfully applied in treatment of neurodegenerative diseases, eye diseases, cardiovascular disease, diabetes, liver disease and cancer. Suppression of the host immune system is considered the main challenge in such therapies. In order to avoid the side effects of immunosuppressive drugs,

encapsulating cells into polymeric matrices is considered a promising strategy. Encapsulation systems utilize permeable materials that allow diffusion of nutrients, waste and therapeutic factors into and out of cells, while masking the cells from the host immune response. In our model, we have been encapsulating ARPE-19, human immortal cell line, that was genetically designed to express and secrete CR2-fH protein to test them for safe and effective long term inhibition in vivo. CR2-fH is a complement inhibitor molecule that has been recently found to express promising therapeutic effects in both in vivo and in vitro models of Age-related Macular degeneration (AMD). Furthermore, human skeletal muscle differentiating cells (skMDC) that were recently used in biomedical research to investigate skeletal muscle behavior, function, and ability to be implemented in tissue regeneration field for further applications of disease advanced therapies.

In this study we hypothesize that alginate encapsulation using high voltage method can be enhanced and advanced further to use it in different clinical approaches and applications. The present study shows the successful formation of alginate-poly-L-ornithine microcapsules using the above-mentioned method, according to specific parameters, to produce microcapsules about 200 μm in diameter. The microcapsules derived from this encapsulation technique according to our hypothesis can be freeze dried without harming the shape of the microcapsules in which they retain the original shape after hydration. The main purpose of lyophilization is to increase the shelf-life storage of encapsulated biomaterials as well as preserve its activity to be used for treatment. Moreover, the technique has the ability to preserve the metabolic activity of genetically engineered ARPE-19 cells and skMDC cells resulting in effective and safe long-term

drug delivery for treatment. In addition, hydrogel systems have been utilized in combination with the previous approaches, lyophilized microcapsules and encapsulated cells, for more improvements in regenerative medicine and targeted delivery therapy fields.

TABLE OF CONTENTS

Dedication	iii
Acknowledgements	iv
Abstract	v
List of Figures	x
CHAPTER I: Introduction	1
1.1 Microencapsulation and Drug Delivery Systems.....	1
1.2 Freeze drying—Lyophilization	4
1.3 Cell encapsulation	5
1.4 Hydrogel.....	7
CHAPTER II: The role of lyophilization process in advancing microencapsulation technique	12
2.1 Background	12
2.2 Materials and Methods	13
2.3 Results	16
2.4 Discussion	18
CHAPTER III: The effect of electrospray method of encapsulation on the viability of living cells within alginate based microcapsules	22
3.1 Background	22
3.2 Materials and Methods	23

3.3 Results	27
3.4 Discussion	30
CHAPTER IV: Encapsulated cell technology-based delivery of complement inhibitor reduces choroidal neovascularization in a mouse model.....	41
4.1 Background	41
4.2 Materials and Methods	43
4.3 Results	49
4.4 Discussion	51
CHAPTER V: Involvement of hydrogel systems in advancing alginate based microcapsules.....	59
5.1 Background	59
5.2 Materials and Methods	60
5.3 Results	61
5.4 Discussion	61
CHAPTER VI: Summary and future work	64
References	67
Appendix A- permission to reprint	90

LIST OF FIGURES

Figure 1.1 The chemical structure of sodium alginate polysaccharide building units	10
Figure 1.2 Schematic illustration of cell encapsulation technology.	11
Figure 2.1 Light microscope and SEM images of empty alginate microcapsules.....	20
Figure 2.2 Release profiles comparison of loaded BSA within non-lyophilized and lyophilized alginate microcapsules at different incubation temperatures.....	21
Figure 3.1 Effect of electrospray method on encapsulation of ARPE-19 cells.	33
Figure 3.2 Viability of ARPE-19 cells after encapsulation and Recovery.	34
Figure 3.3 Viability of ARPE-19/CR2-fH cells after encapsulation and Recovery.	35
Figure 3.4 Viability of skMDC cells after encapsulation and Recovery	36
Figure 3.5 The effect electrospray method of encapsulation on Desmin expression in skMDC cells.....	37
Figure 3.6 The effect electrospray method of encapsulation on MyoD expression in skMDC cells.....	38
Figure 3.7 The effect electrospray method of encapsulation on Pax-7 expression in skMDC cells.....	39
Figure 3.8 Viability of encapsulated ARPE-19 cells after cryopreservation.....	40
Figure 4.1 Encapsulation technique development to encapsulate genetically modified ARPE-19 cells to deliver CR2-fH.....	55
Figure 4.2 Assessment of delivering CR2-fH using encapsulation technique in the eye ..	56
Figure 4.3 Immune response measurements against CR2-fH produced in the eye	57
Figure 4.4 Delivered CR2-fH through encapsulation technique reduces CVV and complement activation	58

Figure 5.1 Lyophilized microcapsules and their rehydration after mix with collagen hydrogel.	63
Figure 5.2 Viability of encapsulated ARPE-19 cells embedded within type I collagen hydrogel	63

CHAPTER I

INTRODUCTION

1.1 Microencapsulation and Drug Delivery Systems

Drug delivery systems (DDS) are engineered approaches or technologies for controlled release of therapeutic agents and/ or delivery of them to target organs in the body in order to eliminate or minimize systemic side effects. Recently, DDS have been improved steadily, and the interest in controlled release dosage forms has increased. DDS that include carriers, composed mainly from lipids and/or polymers, and their associated therapeutic agents on macro, micro, and nano scale are primarily designed to manipulate biodistribution and pharmacokinetics of the associated drugs. In addition, DDS are functioning as sustained release systems especially with advances in biotechnology related to macromolecules such as proteins, peptides, oligonucleotides, and plasmids ^{1,2}.

Microencapsulation systems are one of DDS that are recently getting more attention in advancement for targeted delivery of therapeutic agents. Microcapsules yielded from this technique are characterized by their semipermeable membrane that allows diffusion of the encapsulated materials from the inner core. The permeability of the microcapsules can be adjusted by coating with one or more layers which provide a controlled release property or add protection of the encapsulated materials. There is a diversity of materials that can be encapsulated successfully for different clinical

applications such as peptides, proteins, enzymes, and antibiotics. Properties of microcapsules (size and shape) are controlled by different parameters such as applied voltage, spraying distance, flow rate, method of encapsulation, and polymer concentration³. The synthesis procedures can vary such as electrospray method, emulsification, jet flow, and solvent evaporation; which result in microcapsules with different morphologies and shapes including spheres, cubes, rods, and irregular patterns³⁻⁵. There are two main categories in the field of electro-hydrodynamics: electro-spraying and electro-spinning.

Microparticles, as drug delivery systems, have been developed due to the advancement of pharmaceutical materials technology that allowed creation of polymeric microcapsules using electrically charged fluids of different natural and synthetic polymers. The polymeric microcapsules have distinctive properties in terms of shape, particle size, drug loading, and profile release⁶. Currently, there are a wide range of polymers that are used for microencapsulation technology including sodium alginate, chitosan, poly-lactic-co-glycolic acid (PLGA), poly-ethylene glycol (PEG), poly-l-ornithine (PLO), and poly-l-lysine (PLL)⁷⁻¹². Unique properties of each polymer such as biocompatibility, viscosity, reactivity with the encapsulated materials, and charge; make it unique for its desired application.

All the different encapsulation procedures share the same methodology concept. One of the polymers used for encapsulation is placed in a positively charged syringe attached to a high voltage generator, and the flow rate of the polymer is controlled by using a syringe driver or pump where the polymer is extruded to a grounded gelling bath. A cone jet is formed at the needle tip due to application of an electric polarization stress

(electrically conductive solution passes through electrical potential difference), flow and gravity. The cone jet is a formation of conical shape of liquid at the needle tip where the charged particles of the liquid accumulate at the apex of the cone. Once a minimal steady state has been reached of both flow and electrostatic voltage, the charged particles separate from the apex and break into reproducible droplets. The material's nature and properties plays main role in this stage of the procedure^{13,14}. Without applying electrical forces to the procedure, the droplet will be controlled by the surface tension of the liquid polymer and effect of the gravity¹⁵. The formed droplet, as micro or nanoparticles, will finally be collected in a grounded solution (as in electrospray method) or device (as in electrospinning method). Both methods are becoming more popular as methods of drug delivery because they can be easily adjusted or altered to form particles possessing a desired release rate and pharmacokinetics. On the other hand, other methods of encapsulation may require additional steps such as heat, shear stress, and pressure which might negatively affects the encapsulated therapeutic agents by decreasing its functionality or degrading its structure³. Our method of interest in this work is the electrospray method to produce spherical microcapsules using sodium alginate as a primary polymer.

Alginate is a natural polymers and it is used widely in microcapsule formation because of its unique properties including low toxicity, biocompatibility, mechanical stability, bioadhesive properties, gelling properties and abundance^{2,16,17}. It is a naturally occurring polysaccharide extracted from brown seaweed, and it's chemical structure is composed from a linear copolymer of (1–4)-linked β -D-mannuronic acid and α -L-guluronic acid as it is described in Figure 1.1^{10,18–23}. Different applications of alginate

has been explored such as its usage as coating material, preparation of controlled release drug delivery systems including microspheres, gels, and membranes; as well as forming a hydrogel when crosslinked to cations such as calcium or barium^{16,24,25}.

1.2 Freeze drying—Lyophilization

Lyophilization, or freeze drying, is a technique often used mainly to enhance the stability and shelf life of pharmaceutical products. This technique is based on dehydrating a pre-frozen material at low temperature and low pressure, and resulting in formation of a porous structure. In addition to preserve color, scent, and shape of lyophilized materials, freeze drying technique keeps the biochemical characteristics and pharmacological properties to the greatest extent. Freezing and drying stresses applied by lyophilization could tend to destabilize or denature protein compounds, but different proteins endure freezing and drying stresses to various degrees. Although lyophilization of protein formulations is a challenging process, it is considered a common procedure in the pharmaceutical field to improve stability of therapeutic proteins especially to maintain their original characteristics upon reconstitution^{26–29}. Freeze drying has been used previously to dehydrate proteins, plasma, vaccines, blood platelets, and sperm cells and it has been shown to increase their shelf-lives^{29–34}. Also, seeking activity preservation of most biological materials containing live bacteria and viruses through freeze drying become widely used to ensure long term preservation.

The lyophilization process is typically performed initially by freezing the biological material to freezing temperature range of (-50°C)-(-80°C), followed by drying the biological material under vacuum to remove frozen water from the material at two

different stages of drying. Primary drying at temperatures below 0°C and the drying rate at this stage is limited to avoid foaming of the product due to the high temperature and the excess liquid (solvent) amount at this stage. Then the secondary drying stage begins at temperatures above 0°C to bring the residual moisture of the biological material to an optimum level. If the moisture content is above or below the optimum value, the effective life of biological material will be reduced³⁵⁻³⁷.

Freeze drying of microencapsulated human retinal pigment epithelial cells (ARPE-19) has been shown to be successful in a recent study³⁸. It has been demonstrated that the cells were able to retain their viability and structural integrity after freeze drying³⁹. Cells were encapsulated in polycation coated alginate microcapsules and lyoprotective solutions such as trehalose that protects proteins, cellular membrane, and nucleic acids from the harmful effects of the dehydration^{32,40-43}. Trehalose replaces the cellular water molecules and forms intracellular glass to protect the viability of the cells from the damage that can be caused by the dehydration. Also sugars and antioxidants can be added in different protocols for the same protection purposes⁴³⁻⁴⁷.

1.3 Cell encapsulation

Cell encapsulation technology refers to entrapment of living cells as targeted delivery systems. Encapsulated cells can be used for two purposes: delivering living, functional cells to the target organs for tissue engineering purposes; delivering therapeutic molecules produced from genetically engineered cells to a targeted tissue or organ. More important, this technique provides the advantage of long term targeted treatment without the necessity for recurrence. As described in Figure 1.2, cells after

encapsulation will be entrapped within a polymeric semipermeable membrane that allow influx of nutrients and oxygen; and outflux of metabolic waste products and therapeutic molecules. The membrane also protects the cells from the host immune system⁴⁸.

Cell encapsulation technique is a promising approach in the development of cell based therapies to treat acute and chronic illnesses. Recently, research studies are focused on encapsulating different cell types such as ARPE-19 cells, peripheral blood mononuclear cells, non-human primate multipotent stromal cells, mesenchymal stem cells, and islet cells^{39,49-52}. Alginate polymer is widely used in encapsulating different types of cells and the purification degree of alginate is playing a great role in the success of cell encapsulation process. It has been shown that poorly purified alginate resulted in failure of many microencapsulation processes; indeed, ultra-purified raw product (clinical grade) of alginate in combination with PLO showed to be highly proficient in rendering immunity stimulation of the host body where the mannuronate dimeric blocks of alginate covalently bound to PLO⁴⁹.

In a previous clinical study it has been shown that cells encapsulated within alginate/PLO fabricated microcapsules had enough durability and robustness over a long period of time lasts up to 5 years without any immunity sensitization⁴⁹. The team of this study was able to retrieve physically intact microcapsules after 5 years post-transplant from one of the patients with type I diabetes included in the study. Although the study was successful in transplanting encapsulated islet cells in diabetic patients for a long period of time without any adverse effects, no therapeutic effect has been recorded including regeneration of native islet cells or downregulation of plasma glucose levels.

However, such a successful clinical study brings motivation and hope that this technique can be developed to play a vital role in cell targeted therapy in the near future⁴⁹.

1.4 Hydrogel

Hydrogels are composed of hydrophilic polymer chains that form a three-dimensional system with high water content. The characteristics and properties of each hydrogel depend on the type of polymer used to prepare it, and also can define the purpose of use or the results to be pursued of each application. These properties are varied such as: biocompatibility, elasticity, capability to mimic extracellular matrix (ECM), and adaptable chemical properties^{53–55}. Polymers used in preparing hydrogels are classified in two categories: naturally derived from materials such as collagen, alginate, chitosan, and hyaluronic acid or synthetically derived from materials such as poly hydroxyethyl methacrylate (poly HEMA) and poly ethylene glycol (PEG)^{56,57}. Hydrogels are gaining attention in biomedical research field and regenerative medicine due to their ability to serve as cell and drug delivery therapies, and due to the advancement accomplished in biomaterial systems which set the foundation for therapeutic strategies^{54,58–62}.

Stem cell therapy using hydrogel as a bioactive material is one of the important applications of hydrogel where it is known as regulation of stem cell fate in the field of cell delivery therapy. Hydrogels act as platform that allows better viability, proliferation, and retention of the stem cells^{63–67}. The similarity in the structure between hydrogel scaffolds and extracellular matrix of many tissues is beneficial and increases the

successfulness rate of this approach in engineering tissue replacements; as well as in drug and growth factor delivery⁶⁸.

Usage of natural polymers in preparing hydrogel scaffolds is becoming more popular in regenerative medicine recently. Collagen is considered one of the most commonly used natural polymers in this field due to its biocompatibility, biodegradability, and high versatility⁶⁹⁻⁷¹. It is one of the main components of extracellular matrix proteins existing in the mammalian tissue, and it is derived from skin and tissue of vertebrate species^{67,72,73}. It has been shown previously that type I collagen based hydrogels can cooperate with polyacrylamide to create matrix models of scars which considered soft matrices that exhibit less cell to cell noise. Moreover, type I collagen is able to covalently cross-link to protein patterns to stimulate interactions between the hydrogel surface and the cells^{74,75}. Collagen hydrogels have been used with great success as three-dimensional media for cell culture and showed promising results acting as scaffolds for engineered tissues and tumors. More important, adjustment of quantitative characteristics of collagen hydrogel properties is a critical phase to fulfill engineering requirements and match specific tissues in order to be considered as viable tissue mimics⁷⁶.

My studies aim to further investigate different approaches to test the hypothesis that microencapsulation technique is a unique tool or device which could be advanced to fulfill the necessity of different clinical applications and therapies. These studies are described in the following chapters:

- Chapter II: The role of lyophilization process in advancing microencapsulation technique.
- Chapter III: The effect of electrospray method of encapsulation on the viability of living cells within alginate based microcapsules.
- Chapter IV: Involvement of hydrogel systems in advancing alginate based microcapsules.




Figure 1.1 The chemical structure of sodium alginate polysaccharide building units. (G) Glucuronic acid, and (M) Mannuronic acid. Image produced by the Food and Agriculture Administration of the United Nations.




Figure 1.2 Schematic illustration of cell encapsulation technology.
 (Reproduced with permission from Bhujbal SV, de Vos P, Niclou SP. Drug and cell encapsulation: Alternative delivery options for the treatment of malignant brain tumors. *Advanced Drug Delivery Reviews*. 2014;67-68:142-153. doi:10.1016/j.addr.2014.01.010)

CHAPTER II

THE ROLE OF LYOPHILIZATION PROCESS IN ADVANCING MICROENCAPSULATION TECHNIQUE¹

2.1 Background

Targeted drug delivery and controlled release delivery are considered key areas in drug delivery systems. Advancements in technology are becoming more focused on precisely targeting therapeutic agents to the exact cell, tissue, or organ; and in controlling the fate of a therapeutic agent entering the body⁷⁷. The encapsulation method is a major factor in encapsulation and release of therapeutic agents. Other factors also control the characteristics of microcapsules; the type of polymer including its molecular weight, viscosity, and surface charges contribute in defining its characteristics as well as the characteristics of formed microcapsules⁷⁸. Using electrospray method as a method of fabrication of polymers is the method of choice in this study. Also, alginate is the core polymer used to form microcapsules in adjacent to poly-l-ornithine which is used as a double coat to increase the integrity and enhance the selective porosity of the microcapsules^{79,80}. In this work, we hypothesized that lyophilization of A-PLO microcapsules might advance this technology and enhance its usage for a variety of applications.

¹ Parts of this chapter have been excerpted from the following research article:
Belhaj M, Menon V, Rohrer B, Potts J. Alginate Microcapsule Technology and Impacts on Cell Therapy Development. *Microsc Microanal.* 2017;23(S1):1214-1215.

Lyophilization is a process that operates at different conditions and temperatures which may result in products with different characteristics^{26,81,82}. However, lyophilization has been used widely to preserve different biological materials used for a variety of clinical purposes such as antibiotics, vaccines, proteins, and cells^{31,35,36,45,83}. Moreover, lyophilization is a promising procedure in maintaining different therapeutics, including pharmaceuticals and biological materials, in a dry form for long-term storage, transport, and rehydration at the time of clinical administration⁸⁴.

2.2 Materials and Methods

Microencapsulation:

Electrospray Method was used to prepare the microcapsules^{7,85,86}. Sodium alginate (Sigma-Aldrich, St. Louis, MO, USA) was mixed under sterile conditions at a concentration of 2% w/v. The resulting mixture was purified by filtration at 0.2 μ m. Human platelet lysate (HPL) (Cook Biotech) was added to the alginate and small aliquots (280 μ L) of filtered alginate and HPL mixture were loaded into a 3cc syringe and attached to a syringe pump. Alginate-poly-Ornithine (A-PLO) microcapsules were produced by a one-step method. Polymer solution of poly-L-ornithine (Alfa Aesar L-ornithine hydrochloride 99%) was mixed at a 0.5% w/v in 0.15 M calcium chloride (CaCl₂) (Sigma-Aldrich). The pH was buffered accordingly by 0.1 M HEPES.

A volume of 30 mL of the gelling solution was placed in a beaker below the syringe pump as a gelling bath, with a needle-to-bath working distance of 7 mm (spray distance). A high voltage generator was attached to the tip of 30cc blunt tip needle (purchased by Amazon Supply, Seattle, WA, USA) with a ground placed in the CaCl₂

solution. Next, a constant voltage was set on the high voltage generator to pass a field of current through the needle tip attached to the syringe. The syringe pump was started to push the filtered alginate solution through the needle tip and into the CaCl_2 gelling bath with a flow rate of (60 mm/h). As the extruded alginate was pushed by the syringe pump, it passed through the positively charged needle into the negatively charged CaCl_2 gelling bath creating spherical microcapsules. The voltage remained constant throughout the microcapsulation process by setting the generator prior to starting the syringe pump. Synthesized microcapsules were allowed to gel 12 minutes then removed from the gelling bath post-synthesis and rinsed several times in sterile deionized water to remove any traces of CaCl_2 .

Lyophilization of Microcapsules:

Microcapsules were prepared as mentioned above. The suspended microcapsules in deionized water were frozen using liquid nitrogen. Once the sample was frozen, the beaker was covered with parafilm or a piece of foil and pierced many times to allow escaping of water vapor. Then the sample was placed into a lyophilizer vessel (Labconco, Kansas City, MO, USA) overnight to get a dry powder of microcapsules. The lyophilized microcapsules were rehydrated using deionized water and tested morphologically to ensure complete recovery and shape retaining.

Scanning Electron Microscopy (SEM) of Microcapsules:

It was performed to characterize surface morphology of lyophilized and non-lyophilized microcapsules and examine the effect of lyophilization process on microcapsules morphology. Prior to SEM preparation, microcapsules from both groups

were exposed to UV power at 9,000 μJ x 100 on a plastic petri dish for 30 minutes. An incubation of 24 hours at 4°C was then allowed. Exposure to UV power has been done to increase microcapsule rigidity that insures maintaining the shape during harsh SEM processing. The method of processing was carried out based on a modified protocol using the osmium-tannic acid osmium method (Murphy, 1980). A buffer of 0.1M Na cacodylate, 3mM CaCl_2 at pH 7.2 was used initially to wash microcapsules followed by a buffered fix of 2% paraformaldehyde, 2% glutaraldehyde, and 0.1% ruthenium red.

The microcapsules were then rinsed with (Na cacodylate/ CaCl_2) buffer and placed in a secondary buffered fix consisting of 1% osmium tetroxide and 0.1% ruthenium red. The same buffer solution, (Na cacodylate/ CaCl_2) buffer, was used to rinse fixed microcapsules, and then placed in a series of alternating buffered fixatives containing either 1% tannic acid in 1% glutaraldehyde or 1% osmium tetroxide. Rinses in these buffered fixatives were repeated eight times at 20 min each with rinsing with buffer in between steps. Finally, the microcapsules were rinsed with water to remove any buffer residues, followed by dehydrating in a series of ethanol baths, critical point drying (Tousimis Samdri PVT 3B; Tousimis, Rockville, MD, USA), and gold sputter coating (Cressington 108 Auto/SE; Cressington Scientific Instruments Ltd., Watford, UK). SEM images were taken using a JEOL JSM-6300 SEM at 10 kV (JEOL Ltd., Tokyo, Japan).

Microencapsulation and Release Profile of BSA Protein:

Release profiles of BSA were studied over 10 days from alginate microcapsules formation or from lyophilized microcapsules rehydration at different temperature settings, 37°C and room temperature. In our studies we have elected to study release in

alginate microcapsules before lyophilization and rehydrated microcapsules after lyophilization.

For these experiments, encapsulation parameters were kept constant at 6.0kV initial voltage, flow rate of 60mm/hr, and 7 mm spray distance. Initial BSA protein concentration was kept constant at 1mg/ml. Alginate concentration was also kept constant at 2%, while the CaCl_2 gelling bath was synthesized at 0.15M CaCl_2 as previously listed. As it has been suggested in a previous study held in the lab, pH as well kept constant at 7.3. Microcapsules used for release profiles were not coated with poly-l-ornithine polymer. Post synthesis, microcapsules were rinsed in deionized water to remove excess gelling solution. The microcapsules were then re-covered in 0.5mL deionized water, with time points taken over 10 days. Early time points of 1, 2, 4, 6, and 8hrs were taken to account for early burst release of peptide from the microcapsules. Analysis of peptide concentration was performed using a Micro BCA protein assay kit (Thermo Scientific) with BSA standard solution for our standard curve. All tests were run on a BioTek Synergy 2 spectrophotometer.

2.3 Results

Microencapsulation technique in our lab has been performed using electrospray method under specific parameters to produce ~200 μm microcapsules in diameter. The voltage was 6.0 kV, the flow rate was 60 ml/hour, the spray distance was 7 mm, and 2% concentration of alginate solution. Also, the microcapsules were coated with poly-l-ornithine to increase the integrity of alginate microcapsules. Before processing the microcapsules for electron scanning microscopy, the microcapsules were crosslinked

using ultraviolet cross linker to increase their stiffness in order for the microcapsules to maintain their shape during the preparation protocol for microscopy. As shown in Figure 2.1 A, the microcapsules were spherical in shape at its hydrated state with an average diameter of 200 μm . Microcapsules after encapsulation process were washed thoroughly to remove any traces of CaCl_2 ; then the microcapsules were loaded into lyophilizer for dehydration. Dried microcapsules appeared as white powder, and its structure appeared to be shrunk when examined with light microscopy and SEM as it is shown in Figure 2.1 B.

Adding deionized water to the lyophilized microcapsules led to its rehydration and regaining almost the original spherical shape compared to control microcapsules (before lyophilization). In Figure 2.1 C, rehydrated microcapsules appeared to have rough surface compared to control microcapsules; however, most of the microcapsules retained back their spherical appearance where very few rehydrated microcapsules get burst after rehydration.

Loading efficiency experiments were conducted on four samples. Two identically synthesized sets of microcapsules, one used immediately after encapsulation process and one after rehydration following lyophilization, were both analyzed for release at 37°C and room temperature. Our preliminary data in Figure 2.2, indicated a rapid initial burst of BSA prior to the initial 1 hour time point in the examined samples. Release from non-lyophilized microcapsules at room temperature does not show the initial burst release, and it shows a delayed release until day 6 of incubation when it starts releasing. Previous reports have suggested that the insets of release are at the five hours of release for better appreciation of the rapid release of peptide⁸⁵. The fluctuating release of BSA over all the

samples is not clear. The impact of lyophilization and incubation temperature on BSA release is unknown and must be further investigated in order to determine significance.

2.4 Discussion

A-PLO microcapsules previously showed a great potential as a controlled release delivery system of connexin 43 peptide to increase wound healing rates *in vivo*^{80,85}. Parameters of encapsulation procedure are what control the characteristics of the microcapsules produced. Nature and features of polymers have played an integral role in advancements of delivery systems which defines the characteristics of microcapsules.

Accordingly, in this study we are using electrospray method to produce approximately 200 μm microcapsules by adjusting alginate concentration, flow rate, spraying distance, and voltage rate. Our main goal is to optimize this technology and improve its versatility for variety of clinical applications; therefore, lyophilization is one of the approaches that will be examined in the current study. Lyophilization, freeze drying, has been utilized since 1958 to enhance the pharmaceutical products in order to be utilized at different administration strategies⁸⁷.

As demonstrated through our results in Figure 2.1 that A-PLO microcapsules were successfully lyophilized; not only that but also they were able to retain their morphology back after rehydration. The microcapsules shown were empty, not loaded with any material. Proteins were one of the biological materials to be lyophilized successfully for stability and storage purposes. Although lyophilization was ideal to prepare solid protein pharmaceuticals achieving stability at acceptable storage shelf life; however, this process generates different stresses such as temperature changes, vacuum

forces, pH changes, and formation of ice crystals. Protein denaturation at various degrees might occur as a result of exposure to all of the stresses listed earlier^{26,87}. Numerous research studies have been conducted to identify critical effects of protein lyophilization on protein stability and effectivity^{37,82,88}. It has been shown that the need for stabilizers is very critical in maintaining encapsulated biological materials' effectivity during freeze drying and storage afterwards as well as preserve the microcapsules structure^{40,42,89}. The results shown in our study indicates that the lyophilization process was capable of preserving the original structure of our alginate-PLO microcapsules. However, further investigations needed to verify the effects lyophilization on characterizations of microcapsules which serve as controlled release delivery system.

Release profiles of biomaterials have proven to be controlled by different factors including encapsulation parameters and incubation environment. As a result, it has been previously shown that release of α CT1, a low molecular weight peptide, can be controlled by altering extrusion parameters or by including an additional polymer coating to in order to interfere with diffusion pathway⁸⁵. According to our preliminary data, the effect of lyophilization on release of BSA is not clearly understood. In addition, the change in incubation temperature presumed to have an effect that was not clearly correlated to the control of BSA release from alginate microcapsules. Further investigations are highly recommended to identify a clear vision on the effect of lyophilization on releasing of encapsulated biomaterials which will dramatically affect the feasibility of lyophilization as technique intended for long term storage of encapsulated therapeutics.




Figure 2.1 Light microscope and SEM images of empty alginate microcapsules. (A) Microcapsules before lyophilization in a hydrated form and spherical shape with a diameter of $\sim 200\ \mu\text{m}$. (B) Lyophilized microcapsules that appear shrunk in a dehydrated form. (C) Lyophilized microcapsules were rehydrated by adding DI water where the microcapsules retain their spherical shape. Scale bars are $100\ \mu\text{m}$ (LM) and $10\ \mu\text{m}$ (SEM).




Figure 2.2 Release profiles comparison of loaded BSA within non-lyophilized and lyophilized alginate microcapsules at different incubation temperatures.

All 2% alginate microcapsules were loaded with BSA at concentration of 1 mg/ml. The microcapsules were synthesized and gelled in a 0.15M CaCl_2 bath at a pH of 7, a flow rate of 60 mm/hr, and a voltage of 6.0 kV. (A) Comparing release profiles of BSA in water at 37°C between non-lyophilized and lyophilized microcapsules. (B) Comparing release profiles of BSA in water at room temperature between non-lyophilized and lyophilized microcapsules. Measurements were examined using Micro BCA protein assay at 562nm.

CHAPTER III

THE EFFECT OF ELECTROSPRAY METHOD OF ENCAPSULATION ON THE VIABILITY OF LIVING CELLS WITHIN ALGINATE BASED MICROCAPSULES²

3.1 Background

Currently available drug delivery systems cannot fulfill the demand of several diseases for tight regulation of therapeutic factors. Accordingly, cell therapy shows a potential to serve as a new approach of delivery systems for multiple diseases including neurodegenerative diseases, diabetes, and muscle diseases^{48,90}. Genetically engineered cells, stem cells, and primary cells are the main focus of recent research studies with the aim of avoiding the implant rejection by host immune response and maintaining cell viability. Therefore, cell encapsulation emerges as a promising therapeutic strategy for targeted management of numerous health problems. The goal of cell encapsulation is to serve as a drug delivery tool, sustained release of therapeutics from encapsulated cells, and regenerative medicine tool, delivering cells to particular tissues^{49,90}. Utilizing encapsulated cells as a therapeutic application was pioneered by Lim and Sun early in 1980 when they demonstrated the ability of inducing normal glycemic levels in diabetic rats by implanting microencapsulated islets⁹¹.

² Parts of this chapter have been excerpted from the following research article: Belhaj M, Menon V, Rohrer B, Potts J. Alginate Microcapsule Technology and Impacts on Cell Therapy Development. *Microsc Microanal.* 2017;23(S1):1214-1215.

Our aim in this work is utilizing A-PLO microcapsules as a carrier for different cell types genetically modified ARPE-19 cells, expressing inhibitory factor CR2 and CR2-fH, and skMDC cells that might be beneficial for future clinical approaches as delivery systems.

3.2 Materials and Methods

Cells Culture:

Human retinal pigment epithelial cells (ARPE-19), cell line, were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The medium was replaced every 2-3 days, and the cells were passaged after 70%-80% confluence was reached. Cells were used between 24-27 passages.

ARPE-19 cells were transfected using AAV- mediated delivery with plasmid constructs of CR2 and CR2-fH to express CR2 and CR2-fH proteins. These transfected cells were provided by our collaborators, Dr. Baerbel Rohrer's lab, at The Medical University of South Carolina, Department of Ophthalmology. The cells were cultured in High glucose/without L-glutamine- Dulbecco's Modified Eagle Medium (Sigma Aldrich[®]) supplemented with 10% dialyzed FBS (Sigma Aldrich[®]), 2% Glutamine synthetase expression medium (GSEM- Sigma Aldrich[®]), and 0.28µl/ml L-methionine sulfoximine (MSX- Sigma Aldrich[®]). The medium was replaced every 2-3 days, and the cells were passaged after 70%-80% confluence was reached. Cells were used between third and fifth passage.

Primary human skeletal muscle derived cells (skMDC) were obtained from Cook Myosite[®] (Pittsburgh, PA). skMDC were cultured in MyoTonic[™] basal medium supplemented with MyoTonic[™] growth supplement. Cells were cultured according to the supplier recommendations at 37 °C and 5% CO₂ and maintained below 80% confluence. For differentiating the cells, the growth media will be replaced with MyoTonic[™] differentiation media (DMD- Cook Myosite) after cells reach confluence, and exchanged after 2 days. The differentiation will be apparent within 3-4 days following replacing the media.

Cell Encapsulation:

Electrospray method of microencapsulation has been used to encapsulate the targeted cells. In this method, sodium alginate (Sigma-Aldrich) was mixed with DI water under sterile conditions at concentration of 2% w/v and purified by filtration at 0.2 µm. Alginate solution (~300 µl aliquots) were loaded into a 3cc syringe and attached to a syringe pump, and pumped through a needle (30G blunt tip; Small Parts, Inc., Logansport, IN, USA) to a gelling bath placed in a beaker below the syringe at 7 mm of a needle to bath spraying distance. The gelling bath contains a volume of 40 mL of 10 mM HEPES buffered saline containing 100 mM calcium chloride (CaCl₂) (Sigma-Aldrich), and 0.5% w/v poly-L-ornithine (PLO) (Alfa Aesar) that forms a second coating to the microcapsules as one step method for adjusting the porosity. The needle tip connected to a high voltage generator while the gelling bath grounded. By applying high voltage between positive and grounded bath, alginate is extruded from the needle tip to the gelling bath where calcium ions (Ca²⁺) replace sodium ions (Na⁺) forming alginate microcapsules coated with PLO and cells mixed with alginate solution will be trapped

inside the microcapsules. Cells were trypsinized, centrifuged, and washed with 10 mM HEPES buffered saline solution (pH 7.4), and a final cell concentration of 1×10^6 in alginate solution were adjusted. Constant parameters of 60mm/hr flow rate and 6.0kV initial voltage were adjusted to produce microcapsules size of $\sim 200 \mu\text{m}$. The size of the microcapsules can be monitored by adjusting flow rate and voltage applied in which $\sim 150 \mu\text{m}$ diameter microcapsules can be retrieved by applying parameters of 30mm/hr and initial voltage 8kV. Formed microcapsules containing cells were washed with washing solution (10 mM HEPES buffered saline containing 1.5 mM CaCl_2 , pH 7.4) twice, and then incubated with suitable media in a humidified incubator at 37°C and 5% CO_2 .

Cell recovery:

The cells were released from alginate microcapsules by adding 55 mM Sodium citrate in 10 mM HEPES buffered saline (pH 7.4) to the encapsulated cells with gentle shaking for 5 mins at room temperature. In this step, calcium ions will replace sodium ions in the microcapsule structure resulting in diluted sodium alginate and releasing the cells from the microcapsules. Furthermore, the cells were centrifuged at 1200 rpm for 5 mins and incubated with media at 37°C and 5% CO_2 for 24 hrs.

Cell viability (Live/Dead) assay:

Encapsulated cells—after incubating the encapsulated cells for 24 hrs, approximately 30 microcapsules were washed twice with washing solution (10 mM HEPES buffered saline containing 1.5 mM CaCl_2) and stained for live-dead viability. Live/Dead assay kit (Molecular Probes) was used to evaluate the viability of cells after

encapsulation. According to the manufacturer's instructions, CalceinAM indicated viable cells by green fluorescence (excitation/emission ~495/515 nm), whereas Ethidium homodimer-1 indicated dead cells by red fluorescence (excitation/emission ~495/635 nm). Encapsulated cells in washing solution were mixed with Calcein AM and Ethidium homodimer-1 at final concentrations of 2 μ M and 4 μ M respectively, and incubated for 30-45 mins in dark at room temperature. After staining, microcapsules were washed twice with washing solution and imaged using Invitrogen EVOS FL Auto Cell Imaging System (Thermo Fisher Scientific, Waltham, MA).

Encapsulated ARPE-19 cells in hydrogel— hydrogel was washed with PBS to remove any media traces and stained for encapsulated cells viability. Live/Dead assay kit (Molecular Probes) was used to evaluate the viability of cells after encapsulation and mixing with collagen hydrogel. According to the manufacturer's instructions, CalceinAM indicated viable cells by green fluorescence (excitation/emission ~495/515 nm), whereas Ethidium homodimer-1 indicated dead cells by red fluorescence (excitation/emission ~495/635 nm). A cocktail of Calcein AM and Ethidium homodimer-1 at final concentrations of 2 μ M and 4 μ M respectively was added to the hydrogel and incubated for 30-45 mins in dark at room temperature. After staining, excess amount of staining solution was washed with PBS and we imaged the encapsulated cells in the hydrogel using Invitrogen EVOS FL Auto Cell Imaging System.

Immunofluorescence analysis of the skMDC:

skMDCs were trypsinized from confluent plates and then grown overnight on 24 well plate with initial seeding density of 10,000 cells per well. Cells then were fixed with

2% formaldehyde for 5 minutes and permeabilized with PBS- 0.1% Triton X-100 for 10 minutes. Fixed cells were washed with PBS and incubated at room temperature with Glycine then with 5% BSA/PBS for 30 minutes each in order to stop the fixation reaction using formaldehyde, and block non-specific protein binding accordingly. Cells after blocking were washed and incubated overnight at 4C° with Desmine, MyoD, and Pax-7 (Santa Cruz Technologies, Inc), 1:50 each. After washes, cells were incubated with 1:100 Texas Red (TX)-conjugated goat anti-mouse antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) together with DAPI for nuclear staining (Invitrogen/ Life Technologies). Samples were analyzed on Invitrogen EVOS FL Auto Cell Imaging System (Thermo Fisher Scientific, Waltham, MA) in the Instrumentation Resource Facility (IRF) at the USC School of Medicine. Cells were observed with a 10X objective lens, using a DAPI filter to visualize nuclei and a TX filter for Desmin, MyoD, and Pax7. Results were observed in three separate experiments.

3.3 Results

Encapsulation of ARPE-19 cells:

Electrospray method at voltage rate of 6.0 kV enabled us to encapsulate ARPE-19 cells within 200 µm A-PLO microcapsules as it is shown in Figure 3.1(B). Encapsulated cells were then incubated in 10% FBS DMEM media at 37°C/ 5% CO₂ for a period of time, microcapsules were imaged at different time points 3days, 6 days, and 20 days. As it is shown in Figure 3.1 the encapsulated cells were proliferating inside the microcapsules and appeared as clumps of cells. After 20 days of incubation, the microcapsules start to burst and cells find their way outside the microcapsules as shown

in Figure 3.1 (E). We revealed that FBS supplement in media has to be decreased from 10% to 2% to slow down their proliferation to prevent losing the microcapsules.

ARPE-19 cells viability test after encapsulation and their recovery from microcapsule structure:

After encapsulation and incubation in 10% FBS media for 3 days, cells were stained for live/ dead assay to evaluate their viability. Green color indicates viable cells whereas dead cells were stained red. In Figure 3.2 (A), Cells in green (viable) were more than dead cells (Red).

We examined the ability of the cells to be recovered back from microcapsules and their ability to be incubated and proliferate after exposure to high voltage rate during encapsulation. Encapsulated cells were incubated in 55 mM sodium citrate solution HEPES buffered saline. Sodium ions from the solution will replace calcium ions attached to alginate which will convert it into a soluble form and allow us to collect cells after centrifugation. Recovered cells were cultured back in media and incubated at 37°C and 5% CO₂. Cell showed viability after being cultured back in their desired media, and we were able to passage it up to 3 times after recovery.

Encapsulation of genetically modified ARPE-19 cells, viability, and recovery:

Genetically modified ARPE-19 cells were provided by our collaborators from MUSC which expresses CR2 and CR2-fH proteins. Cells were encapsulated successfully as indicated in Figure 3.3 B and examined for viability where the viable cells were highly found in our sample; dead cells were barely found in our sample of live/dead assay as

shown in Figure 3.3 (A). Cells were then recovered from microcapsules and incubated in media as shown in Figure 3.3 (C) where the cells showed viability after recovery and they were passaged for up to 3 times.

Encapsulation of skMDC cells, viability, recovery, and differentiation:

In Figure 3.4, skMDC cells encapsulated using the same method of encapsulation, and the encapsulated cells examined for viability where in Figure 3.4 (C) most of the cells were green indicating its viability.

Cells were recovered and were recovered back in media as shown in Figure 3.4 (D). In addition, a group of recovered cells were cultured in differentiating media Figure 3.4 (E) where the cells showed viability in the new media and incubated to give them a chance to differentiate into skeletal muscles.

Staining skMDC cells for myogenesis markers Desmin, MyoD, and Pax-7:

The main purpose of staining the cells for myogenesis markers is to examine the effect of encapsulation process has on the cell viability and metabolic activity. Staining skMDC cells against the myogenic markers showed that the cells from the entire 3 group: Control (before encapsulation), recovered, cells in differentiation media (differentiated), were able to express MyoD, desmin, and Pax7. Nuclei were stained blue (Dapi) while the targeted protein stained in red as it shown in Figure 3.5.

Freezing the encapsulated cells was another aspect that we utilized with ARPE-19 cells. After encapsulation and incubation in media for 3 days, we changed culture media to a freezing media where the encapsulated cells mixed with and prepared for freezing.

Vials of encapsulated cells were stored in Mr. Frosty and kept at -80°C for up to one week. Finally, the encapsulated cells were thawed and cultured back in supplemented media, and then they were tested for viability using live/dead assay. As shown in Figure 3.8, the cells were stained in green indicating that their viability still preserved; red signal indicating dead cells was barely expressed.

3.4 Discussion

Since enhancement of A-PLO microcapsules is the main goal of this work, cell encapsulation is another approach in which we utilize our microcapsules to encapsulate different type of cells. The polymer membrane serves as immunoisolation barrier for the cells intended for applications as therapeutic delivery system and regenerative medicine. Indeed, there are some preliminary clinical studies of prolonged survival of cells; however, cell encapsulation technology has not yet accomplished the expected clinical advances^{49,92}. Recently, a wide range of research studies focused on investigating the effects of different fabrication methods and variety of polymers on viability and effectivity of variety of encapsulated cells^{47–50, 91–102}. In this work, we investigated the effect of electrospray method of fabrication on cells encapsulated in A-PLO. Cells used for this study were intended for therapeutic agent delivery system, ARPE-19/ CR2-fH, and for regenerative medicine, skMDC.

Encapsulated ARPE-19 cells through our fabrication method showed that the viability and effectivity of cells was preserved after encapsulation in Figure 3.1 and Figure 3.2. Consequently, genetically modified ARPE-19 cells, steadily express CR2-fH protein, proved to be viable and effective after encapsulation in Figure 3.3. ARPE-

19/CR2-fH cells were generated in order to develop innovative therapeutic tool targeting treatment for age-related macular degeneration (AMD). Factor H serve as an inhibitory agent of the alternative pathway (AP) of complement activation, whereas polymorphisms in FH are associated with AMD risk. CR2-fH, the novel recombinant form of fH, has found to be effective inhibitor in different AP-dependent disease models such as collagen-induced arthritis, and acute lung reperfusion injury. Importantly, CR2-fH has shown that it is able to reduce the choroidal neovascularization (CNV) *in vitro* when injected intravenously^{105–109}. Encapsulated ARPE-19 cells expressing CR2-fH showed to be effective *in vivo* as therapeutic agent delivery system. It has been presented that CR2-fH was secreted in the eye from the encapsulated cells after intravitreal injection, and was effective in reducing compliment activation and can decrease CNV in mouse⁹³.

Primary human skeletal muscle cells (skMDC) are considered and targeted for cell therapy¹¹⁰. Encapsulation of skMDC cells might be useful as a potential therapeutic tool for treatment of severe muscle diseases and conditions. The results of this study demonstrated that cells viability and morphology characteristics were preserved after encapsulation in Figure 3.4. It was been showed that cells were recovered from microcapsules in which it continue to proliferate indicating that encapsulation process did not affect its biological characteristics. In addition, cell staining for the expression of myogenic markers such as desmin, MyoD, and Pax-7 showed that the cells in all the samples were able to express the targeted proteins Figure 3.5, 3.6, and 3.7 to proof that encapsulation technique does not affect the metabolic activity of encapsulated cells.

Moreover, we showed in this work that cryopreservation of A-PLO encapsulated cells is a feasible for future therapeutics delivery and regenerative medicine projects.

Previous research studies have been demonstrated that cryopreservation is a promising approach for preserving encapsulated cells for future optimization¹⁰¹. Encapsulated ARPE-19 cells have been shown to preserve the viability and biological activity after cryopreservation Figure 3.8. The goal of this approach was to generate the foundation for cryo-banking for future utilization of encapsulated cells in regenerative medicine and therapeutics delivery projects.




Figure 3.1 Effect of electrospray method on encapsulation of ARPE-19 cells. (A) ARPE-19 cells cultured in DMEM media. (B) Encapsulated cells at initial concentration of 1×10^6 cells/ ml after 1 hour of encapsulation. (C) Cells after 3 days of encapsulation. (D) Cells continue to grow inside the microencapsulation after 6 days of incubation in media. (E) Microcapsules became full of growing cells after 20 days of incubation in 10% FBS media. Scale bars = 100 microns.




Figure 3.2 Viability of ARPE-19 cells after encapsulation and Recovery. (A) Live/ dead staining performed on encapsulated cells after 3 days of encapsulation. Viable cells stained in green (CalceinAM), whereas cells in red (Ethidium homodimer) indicates cells with massive membrane damages. (B) ARPE-19 cells after encapsulation and before recovery. Cells were recovered from microcapsules using sodium citrate solution. The recovered cells have been passaged up to 3. Scale bars = 100 microns.




Figure 3.3 Viability of ARPE-19/CR2-fH cells after encapsulation and Recovery. (A) Live/ dead staining performed on encapsulated cells after 3 days of encapsulation. Viable cells stained in green (CalceinAM), whereas membrane damaged (dead) cells in red (Ethidium homodimer). (B) ARPE-19 cells after encapsulation and before recovery. Cells were recovered from microcapsules using a sodium citrate dissolving solution. The recovered cells have been passaged up to 3 times. Scale bars = 100 microns.




Figure 3.4 Viability of skMDC cells after encapsulation and Recovery.

(A) skMDC cells cultured in supplemented MyoTonic media. (B) Encapsulated skMDC cells at initial encapsulation concentration of 1×10^6 cells/ml. (C) Encapsulated cells after 3 days of encapsulation were stained with CalceinAM (2 μ M/ Green) and Ethidium homodimer (4 μ M/Red). Viable cells stained in green whereas dead cells in red. (D) skMDC were recovered from microcapsule structure using citrate sodium solution and cultured back into supplemented MyoTonic media. (E) A Group of recovered cells was cultured in differentiation media to allow them to differentiate and change phenotype. Scale bars = 100 microns.




Figure 3.5 The effect electrospray method of encapsulation on Desmin expression in skMDC cells.

Control cells (before encapsulation), recovered, and differentiated cells were probed for DAPI (Blue) and desmin (Red). Scale bars = 100 microns.




Figure 3.6 The effect electrospray method of encapsulation on MyoD expression in skMDC cells.

Control cells (before encapsulation), recovered, and differentiated cells were probed for DAPI (Blue) and MyoD (Red). Scale bars= 100 microns.




Figure 3.7 The effect electrospray method of encapsulation on Pax-7 expression in skMDC cells.

Control cells (before encapsulation), recovered, and differentiated cells were probed for DAPI (Blue) and Pax-7 (Red). Scale bars = 100 microns.




Figure 3.8 Viability of encapsulated ARPE-19 cells after cryopreservation. (A) Encapsulated cells thawed after freezing at -80°C for 1 week. (B) Encapsulated cells were tested for their viability after freezing. Viable cells were stained in Green (CalceinAM), and dead cells were stained in red (Ethidium homodimer). Scale bars = 100 microns.

CHAPTER IV³

ENCAPSULATED CELL TECHNOLOGY-BASED DELIVERY OF A COMPLIMENT INHIBITOR REDUCES CHOROIDAL NEOVASCULARIZATION IN A MOUSE MODEL

4.1 Background

Age-related macular degeneration (AMD) is a slowly progressing condition that is classified according to the pathological mechanism into two categories, wet and dry AMD. In wet AMD, fluid accumulates in the subretinal space due to choroidal blood vessels invasion through damaged blood barrier (BRB), and the fluid accumulation could cause retinal detachment that consequently lead to photoreceptor deterioration as complications of untreated condition. On the other hand, the pathological mechanisms of dry AMD are still not clearly understood. The main characteristics of dry AMD are degeneration of retinal pigment epithelium (RPE) and choriocapillaries that correlates to the loss of photoreceptor cells. Involvement of genetic and environmental risk factors are responsible on the complexity of AMD¹¹¹. Wet AMD occurrence has been showed to be associated with single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGFa), VEGFR2 receptor, and genes in the proliferation subpathway^{112–115}; however, there is no clear pharmacogenetic association in anti-VEGF therapy between patient's response to the treatment and patient's VEGFa or VEGFR2 SNPs^{116,117}.

³ This chapter have been excerpted from the following research article:
Annamalai B, Parsons N, Belhaj M, Brandon C, Potts J, Rohrer B. Encapsulated Cell Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal Neovascularization in a Mouse Model. *Transl Vis Sci Technol.* 2018;7(2):3-3.

In addition to the multiple SNPs in genes of the complement pathway including polymorphisms in Y402H variant in the complement inhibitor factor H (CFH) which are linked with an increased risk of developing AMD¹¹⁸. According to association between AMD and Y402H, this study focused on investigating complement activation mechanisms in AMD models as well as examining improvements in complement therapeutics for treatment of AMD pathologies.

The complement system is a part of innate immune system that is activated in response to stress and/or injury stimulators. The activation of the complement systems followed by multiple biological molecules activation cascade including C3a and C5a (anaphylatoxins), opsonins C3d and C3dg (opsonization of damaged cells), membrane attach complex (MAC- lysis of cells)¹¹⁹. A complement inhibitor molecule (CR2-fH) has been developed and effectively inhibits complement activation at RPE levels in vitro in AMD models¹²⁰⁻¹²². In addition, CR2-fH has been shown via in vitro models that it was effective in reducing choroidal neovascularization (CNV) development by suppressing complement activation and VEGF production¹²³⁻¹²⁵. Moreover, CR2-fH has shown effectivity as an inhibitor indifferent AP dependent disease conditions such as collagen induced arthritis, and acute lung and ischemia perfusion injury^{126,127}. The inhibitory activity of CR2-fH is prompted due to presence of AP-inhibitory domain that linked to a complement receptor (CR2) and targets the inhibitor fH to bind complement activation products¹²⁸. Importantly, the efficacy and safety of subretinal administration of AAV vector encoding the CR2-fH inhibitor has been confirmed in mouse model of CNV¹²⁹. In the current study, efficacy of delivering CR2-FH using encapsulation technique to encapsulate genetically modified ARPE-19 cells has been examined in mouse CNV

model. The small size of produced alginate microcapsules is required for intravitreal injections into the eye of an experimental mouse.

4.2 Materials and Methods

Cells Culture:

ARPE-19 cells, a human RPE cell line that express the differentiated phenotype of RPE cells. The plasmid constructs of CR2 and CR2-fH were transfected into ARPE-19 cells with FuGene HD transfection reagent according to the manufacturer's instructions (Roche Applied Science, Indianapolis, IN). Stable expression in a mixed population was produced by L-methionine sulfoximine antibiotic selection. Secreted protein into apical and basal compartments was monitored in polarized RPE grown on transwell plates¹²¹. The molecular weight of CR2-fH was examined using sodium dodecyl sulfate acrylamide gel electrophoresis (SDS-PAGE; data not shown). The cells were cultured in High glucose/without L-glutamine- Dulbecco's Modified Eagle Medium (Sigma Aldrich®) supplemented with 10% dialyzed FBS (Sigma Aldrich®), 2% Glutamine synthetase expression medium (GSEM- Sigma Aldrich®), and 0.28 µl/ml L-methionine sulfoximine (MSX- Sigma Aldrich®). The medium was replaced every 2-3 days, and the cells were passaged after 70%-80% confluence was reached. Cells were used between third and fifth passage.

Cells Encapsulation:

Electrospray method of microencapsulation has been used to encapsulate the targeted cells. In this method, sodium alginate (Sigma-Aldrich) was mixed with DI water

under sterile conditions at concentration of 2% w/v and purified by filtration at 0.2 μ m. Alginate solution (~300 μ l aliquots) were loaded into a 3cc syringe and attached to a syringe pump, and pumped through a needle (30G blunt tip; Small Parts, Inc., Logansport, IN, USA) to a gelling bath placed in a beaker below the syringe at 7 mm of a needle to bath spraying distance. The gelling bath contains a volume of 40 mL of 10 mM HEPES buffered saline containing 100 mM calcium chloride (CaCl_2) (Sigma-Aldrich), and 0.5% w/v poly-L-ornithine (PLO) (Alfa Aesar) that forms a second coating to the microcapsules as one step method for adjusting the porosity. The needle tip connected to a high voltage generator while the gelling bath grounded. By applying high voltage between positive and grounded bath, alginate is extruded from the needle tip to the gelling bath where calcium ions (Ca^{2+}) replace sodium ions (Na^+) forming alginate microcapsules coated with PLO and cells mixed with alginate solution will be trapped inside the microcapsules. Cells were trypsinized, centrifuged, and washed with 10 mM HEPES buffered saline solution (pH 7.4), and a final cell concentration of 1×10^6 in alginate solution were adjusted. Constant parameters of 60mm/h flow rate and 8.0 kV voltage were adjusted to produce microcapsules size of ~150 μ m. Formed microcapsules containing cells were washed with washing solution (10 mM HEPES buffered saline containing 1.5 mM CaCl_2 , pH 7.4) twice, and then incubated with suitable media in a humidified incubator at 37°C and 5% CO_2 .

Cells Recovery:

The cells were released from alginate microcapsules by adding 55 mM Sodium citrate in 10 mM HEPES buffered saline (pH 7.4) to the encapsulated cells with gentle shaking for 5 mins at room temperature. In this step, calcium ions will replace sodium

ions in the microcapsule structure resulting in diluted sodium alginate and releasing the cells from the microcapsules. Furthermore, the cells were centrifuged at 1200 rpm for 5 mins and incubated with media at 37°C and 5% CO₂ for 24 hrs.

Cells Viability (Live/Dead) Assay:

After incubating the encapsulated cells for 24 hours, approximately 30 microcapsules were washed twice with washing solution (10 mM HEPES buffered saline containing 1.5 mM CaCl₂) and stained for live-dead viability. Live/Dead assay kit (Molecular Probes) was used to evaluate the viability of cells after encapsulation. According to the manufacturer's instructions, CalceinAM indicated viable cells by green fluorescence (excitation/emission ~495/515 nm), whereas Ethidium homodimer-1 indicated dead cells by red fluorescence (excitation/emission ~495/635 nm). Encapsulated cells in washing solution were mixed with Calcein AM and Ethidium homodimer-1 at final concentrations of 2 µM and 4 µM respectively, and incubated for 30-45 mins in dark at room temperature. After staining, microcapsules were washed twice with washing solution and imaged using Invitrogen EVOS FL Auto Cell Imaging System (Thermo Fisher Scientific, Waltham, MA).

Microcapsule injections:

C57BL/6J mice 8-10 weeks of age of both sexes were used in this study (Jackson Laboratory, Bar Harbor, ME) that were bred in the facility animal house. All the experiments were carried out in compliance with the Guide for the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Animal Care and Use Committee at the Medical University of South Carolina. Prior to

intravitreal injections, mice were placed under using an anesthesia mixture of (xylazine and ketamine, 20 and 80 mg/kg, respectively) applied by intraperitoneal injection. Phenylephrine HCL (2.5%) and atropine sulfate (1%) were used to dilate the mouse's pupils. Under dissecting microscope, an amount of 1 μ L of DMEM containing microcapsules with CR2-fH- or CR2-expressing ARPE-19 cells, native ARPE-19 cells, or no content was injected intravitreally with a 27G needle attached to a Hamilton syringe angled at 45-degree during the injection to avoid the lens. Before injecting the microcapsules, the sclera was punctured at the limbus with a 25G needle. Post injection, antibiotic ointment was applied to the animals' eyes.

Laser CNV:

Argon laser photocoagulation (532 nm, 100-lm spot size, 0.1- second duration, 100 mW) was used one month post injection to create four laser spots around the optic nerve of each eye¹²⁴. Bruch's membrane (BrM) rupture was confirmed by bubble formation at the laser burn site where those lesions only were used for lesion growth assessment¹³⁰. Five days post CNV induction, mouse eyes were imaged using optical coherence tomography (OCT) before scarifying the animals on day 6 for tissue collection.

Dot blot and Western Analysis:

Examining CR2-fH production from transfected cells—Cell lysates were collected after centrifugation (20,000g for 30 minutes at 48C). 25 μ l of total protein was loaded into 96- well plate and samples were transferred on a nitrocellulose membrane using the Bio-Dott Microfiltration Apparatus (Bio-Rad Laboratories, Inc. Hercules, CA).

The dotted membrane blocked in 5% nonfat milk in TBST buffer for 2 hours at room temperature after being washed with Tris-buffered saline and 0.1% Tween 20 (TBST) wash buffer. After blocking, the membranes were incubated overnight with primary antibody against CR2 at 1:1000 dilutions in 5% nonfat milk/ TBST. Horseradish peroxidase- conjugated secondary antibody (anti-rat; Santa Cruz Biotechnology, Inc., Dallas, TX) was used for visualization followed by incubation with Clarity Western ECL Blotting Substrate (Bio-Rad Laboratories, Inc.).

Examining antibody generation in mice against secreted CR2-fH following intravitreal administration of ARPE-19 cells—Supernatants from CR2-fH-expressing cells were added to Laemmli sample buffer and boiled. Two different concentrations of the samples were separated electrophoretically using 4%–20% Criterion TGX Gels (Bio-Rad Laboratories, Inc.). Proteins were then electro-transferred to PVDF membranes, and incubated with primary antibody against CR2, or serum (1:50) from mice treated with intravitreal CR2- or CR2-fH microcapsules. Horseradish peroxidase-conjugated secondary antibody (antimouse IgG and IgM; Santa Cruz Biotechnology) was used for visualization followed by incubation with Clarity Western ECL Blotting Substrate and chemiluminescent detection (Bio-Rad Laboratories, Inc.).

Immunohistochemistry:

Tissue samples of eye lens and anterior chamber were removed from eyecups which was collected as showed in previous study¹²⁴, and the samples were then fixed overnight with 4% paraformaldehyde (PFA). After thoroughly washing in PBS, samples were embedded in Neg-50 cutting medium (Richard-Allen Scientific; Thermo Fisher

Scientific) and sectioned into 14- μ m sections using a cryostat. Blocking solution consisting of (10% normal goat serum, 3% bovine serum albumin factor V, and 0.4% Triton-X in PBS) was used to block the sections before staining overnight with (1:200) CR2 (7G6) antibody at 4°C. after washing the stained sections with blocking solution, secondary antibody was added (Alexa Fluor 488 goat anti-mouse IgG; 1:500; Invitrogen) and mounted using Fluoromount (Southern Biotechnology Associates, Inc., Birmingham, AL). Images were obtained by fluorescence microscope (Zeiss, Thornwood, NY).

Optical Coherence and Tomography:

SD-OCT BiopTigent Spectral Domain Ophthalmic Imaging System (BiopTigent, Inc., Durham, NC) was used to visualize the injected microcapsules in the eye and to analyze CNV lesion size after 5 days of laser treatment as has been described in previous studies^{131,132}. For the analysis of CNV lesion, rectangular volume scan images set at 1.63 1.6 mm were acquired which consists of 100 B-scans (1000 A-scans per B scan) as well as measurements of cross-sectional area of the lesion using the en-face fundus reconstruction tool. The center of the lesion was determined passing through the RPE-BrM rupture with the axial interval positioned at the level of the RPE/choroid complex as described in previous work¹³³. Image J software for data analysis (Wayne Rasband, National Institutes of Health, Bethesda, MD; available online) was used to measure the area around the hyporeflective spot produced on the fundus image, with vertical calipers set at 0.100 mm at the site of each lesion.

C3a ELISA:

Mouse complement C3a ELISA (LifeSpan Biosciences, Inc., Seattle, WA) was used to perform C3a ELISA according to the manufacturer's protocol. The RPE/ choroid tissues were ultrasonicated with 500 μ L ice cold PBS (lysing process) after being thoroughly rinsed with ice cold PBS to remove excess blood. The homogenized sample was centrifuged at 5000g for 5 minutes, and then the assay performed according to the manufacturer's instructions. Standards of C3a were used along with samples, and the absorbance was read at 450 nm using microplate reader.

Statistics:

Unpaired t-tests was used for single comparison, and ANOVA (Fisher PLSD) was used for in-between group analysis with P value = 0.05 for significance (StatView, Cary, NY). Data are reported as mean \pm SEM.

4.3 Results

Encapsulation of genetically modified ARPE-19 cells—secretion of CR2 and CR2-fH was confirmed by dot analysis using collected supernatants from cells grown as stable monolayers on transwell plates as shown in Figure 4.1 (D). Encapsulation of genetically modified ARPE-19 cells within 2% alginate microcapsules was successfully accomplished and it has been confirmed by brightfield microscopy Figure 4.1 (A). Viability of encapsulated cells post encapsulation was assessed using live dead assay that showed a viability of 90% of encapsulated cells Figure 4.1 (C). After dissolving the microcapsule structure using sodium citrate solution, ARPE-19 cells viability has been

assessed by incubating the cells back into their desired media where they have been grown for 90% confluency Figure 4.1 (B).

Delivery of encapsulated ARPE-19 cells intravitreally—the microcapsules size was adjusted through the encapsulation method to produce microcapsules at an approximate size of 150 μ l as an optimum size. The optimum size was ideal to be injected through 27G needle which its inner diameter 210 μ m, and to minimize the microcapsules during intravitreal injection. OCT imaging was performed after injecting the microcapsules in the vitreous of mouse's eye to examine the presence of intact microcapsules in that area as indicated in Figure 4.2 (A). In addition, presence of CR2-fH in the microcapsules as well as its secretion into the vitreous and retinal tissue has been confirmed using immunohistochemistry Figure 4.2 (B). Moreover, it has been confirmed that CR2-fH specifically retained in CNV injury site compared to sites without CNV lesions by dot blot analysis of RPE/choroid fractions as shown in Figure 4.2 (C) and as previously reported in previous study¹³⁴. Examining antibody production against secreted CR2-fH which might access the blood stream has been performed. Mouse serum was collected after 1 month of microcapsules injection and tested for anti-CR2-fH antibody production. It has been shown that neither IgG nor IgM antibodies recognizing CR2-fH could be identified in both CR2-fH microcapsules injected group or control group Figure 4.3. Similar results were previously reported when mice were systemically injected with CR2-fH protein¹³⁵.

Effects of secreted CR2-fH on reducing complement activation and attenuating CNV development—the effect of secreted CR2-fH on CNV lesion size has been evaluated after 5 days of laser-induced photocoagulation. Experimental mice were

injected intravitreally with alginate microcapsules loaded with ARPE-19 expressing CR2, ARPE-19 expressing CR2-fH, native ARPE-19, or empty microcapsules. It has been reported in this study that lesion size in animals received microcapsules with cells expressing CR2-fH reduced significantly ($P=0.02$) compared to other experimental animal groups as demonstrated in Figure 4.4 (A,B). Moreover, ELISA measurements showed significant reduction in C3a levels in mice injected with microcapsules containing cells expressing CR2-fH Figure 4.4 (C). This reduction was expected because it has been known previously that the presence of factor H prevents C3-convertase formation. On the other hand, animals injected with microcapsules loaded with cells expressing CR2, native cells, or empty microcapsules showed an increase in C3a in RPE/choroid fractions.

4.4 Discussion

The focus of this study was to investigate the effectivity of encapsulation technique in encapsulating cells as cell therapy approach to deliver CR2-fH to the eye as a therapeutic strategy for complement dependent diseases. It has been demonstrated through this study that encapsulation technique can preserve the viability of encapsulated ARPE-19 cell within alginate based microcapsules. The encapsulated cells showed secretion activity of CR2-fH that is able to diffuse into the vitreous of the mouse while anti-CR2-fH antibody was not detected. Importantly, secretion of CR2-fH by encapsulated ARPE-19 cells in the eye showed a great effect on reducing CNV development as well as complement activation. Indeed, the obtained results propose the effectivity of encapsulated cell therapy as a therapeutic strategy in treating wet AMD.

It has been recently discussed that the essential aim of encapsulated cells as a therapy approach is to provide a sustain release delivery of therapeutics secreted by encapsulated cells without triggering the immune response against it¹³⁶. According to the present study, the viability of encapsulated cells was preserved and the cells were able to be recovered from the alginate microcapsules to continue proliferating after plating and incubating them back in media. Also, it was confirmed by dot blot analysis that cells secreted CR2-fH for 1 to 2 months after cells being encapsulated and injected; however, antibodies against CR2-fH were not generated by testing CR2-fH antibodies (IgG and IgM). On the other hand, antibodies formation against ARPE-19 epitopes have never been tested in this work because according to a number of clinical trials it has been shown that immunosuppressants are not required while utilizing devices loaded with ARPE-19 cells^{137,138}.

In biotechnology industry world, Neurotech is a biotechnology company focused on the development of encapsulated cell therapy as a therapeutic approach for chronic eye diseases. Neurotech has loaded ARPE-19 cells into a device (NT-501) that has been tested in the eye in which it is delivering CNTF and NT-503, a soluble anti-VEGF-R protein. NT-501 had a good safety results and ongoing trials in glaucoma and Macular Telangiectasia type 2 are taking place to deliver CNTF. However, delivering NT-503 protein using this device has been discontinued in phase II trial because rescue medications were highly required in the treatment arm by a large number of patients according to Neurotech Company. Also, according to Neurotech, it is very important to consider the fact that ARPE-19 cells secrete not only therapeutic proteins but also other proteins consistently that might interfere with the efficacy of the targeted therapeutic

proteins. It has been demonstrated that ARPE-19 cells secrete a diversity of proteins that are involved in maintenance and regulation of the complement pathway, extracellular matrix, inflammatory responses, and angiogenesis¹³⁹. The quantity and the composition of proteins secreted can vary according to the eye under specific disease or treatment application technique; however, the effect of delivering encapsulated ARPE-19 cells on protein secretion and composition has not been determined in this study. Indeed in this work, data show the presence of ARPE-19 in the mouse eye do not interfere with the growth of CNV lesion, but also active CR2-fH showed a protective effect comparing to the inactive CR2, the native cells, or the empty microcapsules Figure 4.4 (B). Moreover, complement activation has not been affected by the presence of ARPE-19 cells in the mouse eye according to the measurements of complement C3a, and this has been determined through the effect of encapsulated native ARPE-19, encapsulated ARPE-19 expressing CR2, and empty microcapsules Figure 4.4 (C). The concentration of microcapsules loaded with ARPE-19 expressing CR2-fH loaded reduced complement activation effectively to the base line levels. The preliminary data of this study showed that approximately 30 microcapsules were responsible on reducing the complement activation and interfere with CNV development. Accordingly, delivering the therapeutic dose of CR2-fH via cell encapsulation technique will promote normal functions of the complement system that is envision as a mediator as a global mediator in immune surveillance, cell homeostasis, and tissue development and repair¹⁴⁰.

ARPE-19 cells have a potential of initiating complications on disease outcomes when they being used a therapeutic approach. The need of delivering anti-complement materials is a necessity, and AAV gene therapy is considered an attractive tool that has

been utilized for disease models¹⁴¹. The expression of the inhibitor in dry or wet AMD should be inducible when required when new CNV lesion being developed, and it can be repressed once the inhibitory effect is no longer needed to avoid the toxic effects of excessive treatment. It has been demonstrated previously that using expression system that can be controlled exogenously, rapamycin or RU486 regulation, or endogenously, hypoxia response element (HRE), could be a feasible approach in controlling CR2-FH overtreatment, especially in case of HRE since hypoxia is highly correlated to wet AMD¹⁴².

This study showed that encapsulated cells therapy has been used to deliver the AP-complement inhibitor factor H using genetically modified ARPE-19 cells to the eye at complement activation sites. The inhibition of AP complement activation reduces complement activation, slows CNV development, and allows retention of physiological levels of complement required for cellular homeostasis and immune surveillance¹⁴⁰.

Future investigations are recommended to examine the feasibility of cell encapsulation-mediated therapeutic delivery of a complement inhibitor as a potential long term inhibition approach in the smoke-induced ocular model¹²⁵, as well as in dry AMD.




Figure 4.1 Encapsulation technique development to encapsulate genetically modified ARPE-19 cells to deliver CR2-fH.

(A) Encapsulated ARPE-19 cells in culture. (B) Recovered cells after dissolving the microcapsule alginate structure and incubated in culture to examine viability. (C) Cell viability within the microcapsules was assessed using live/ dead assay where Calcein AM indicating live cells (Green) and Ethidium homodimer-1 indicating dead cells (Red). Secreted CR2 and CR2-fH towards both the apical and basal side from the stably transfected ARPE-19 cells that were grown as monolayers on transwell plates (secretion assessed from three different cultures).




Figure 4.2 Assessment of delivering CR2-fH using encapsulation technique in the eye. (A) The microcapsules were detected in the eye using optical coherence tomography (OCT). (B) Immunohistochemistry was used to confirm production and diffusion of CR2-fH protein from the microcapsules throughout the retina layers via antibody staining against CR2. Results were compared between uninjected control eyes and injected eyes where the staining was negative in the control. (C) A dot blot of RPE/choroid samples were used to detect CR2-FH after intravitreal injection of the microcapsules in the RPE/choroid region of the eye with CNV lesions or without. CR2-fH was detectable in the samples with CNV lesions comparing to the other group. Results are shown from more than three independent experiments.




Figure 4.3 Immune response measurements against CR2-fH produced in the eye. After one month of injecting encapsulated ARPE-19 cells expressing CR2 and CR2-fH, production of IgG or IgM were not detected. Two different concentrations of expressed CR2-fH were probed against anti-CR2 for the presence of CR2-fH in the supernatants in order to identify the size of the protein (positive control). Serum from both groups, experimental (S-E; injected with CR2-fH capsules) and control (S-E; age-matched animals without injections S-C), was used for probing at 1:50 followed by appropriate secondary antibodies.




Figure 4.4 Delivered CR2-fH through encapsulation technique reduces CVV and complement activation.

Laser induced CNV was performed after one month of injecting encapsulated cells intravitreally. 5 days later, lesion spot sizes were analyzed using OCT and complement activation was assessed for anaphylatoxin C3a using ELISA. (A, B) CNV lesion sizes were reduced in the eyes of experimental group injected with encapsulated ARPE-19 expressing CR2-fH compared to other groups, encapsulated cells expressing CR2, native ARPE-19 without cargo, or empty alginate microcapsules. (C) C3a levels in RPE/choroid fractions were elevated in animals injected with encapsulated ARPE-19 expressing CR2, encapsulated native ARPE-19, and empty microcapsules. Levels of C3a were reduced significantly in animal groups injected with encapsulated CR2-fH expressing cells. Control group represents animals with no CNV lesions. Data shown are average values (6SEM) (n ¼ 3–18 animals per condition as indicated).

CHAPTER V

INVOLVEMENT OF HYDROGEL SYSTEMS IN ADVANCING ALGINATE BASED MICROCAPSULES

5.1 Background

Hydrogels have been utilized as scaffold polymers in different approaches including therapeutic agent delivery and regenerative medicine. There are a variety of applications in which hydrogels have been targeted such as delivery agents for bioactive materials, as three-dimensional structures that can organize cells and direct the formation of a desired tissue with presence of specific stimuli, as well as their application as space filling agents⁶⁸. Properties including mechanical properties, swelling, diffusion, and degradation are important to the hydrogel crosslinked structure in which they are control the hydrogel utilization for each specific approach¹⁴³. Type I collagen has been used widely as a viable scaffold for various applications; however, collagen scaffold properties can vary according to the fabrication protocol used by different researchers. Collagen source and gelation pH are significant fabrication parameters that contribute to identify hydrogel properties and applications^{68,76,144–148}.

The main goal of this study is developing new approach through embedding A-PLO microcapsules in collagen hydrogel as an enhanced delivery system. Through this

study we will show the successful implementation of lyophilized microcapsules as well as our encapsulated cells within collagen hydrogel.

5.2 Materials and Methods

Collagen hydrogels:

To prepare the hydrogels for incorporation of the lyophilized microcapsules, we used type I bovine collagen (Purecol®, Advanced Biomatrix, San Diego, CA), 0.2N HEPES buffer pH9.0, and 10X Minimal Essential Medium (MEM) at proportions of 8:1:1 accordingly. Lyophilized microcapsules were added immediately after mixing the hydrogel contents then aliquots of 300 µl of the mix poured into 24 well plates. The plate was then incubated at 37C° for 30 minutes to let it polymerize, then we added deionized water to keep hydrated.

To prepare the hydrogels for incorporation of the encapsulated ARPE-19 cells, we used type I bovine collagen (Purecol®, Advanced Biomatrix, San Diego, CA), 0.2N HEPES buffer pH9.0, and 10X Minimal Essential Medium (MEM) at proportions of 8:1:1 accordingly. Encapsulated ARPE-19 cells were mixed with freshly prepared hydrogel gel after aspirating the media from the microcapsules. Appropriate aliquots 300-500µl of the mix were poured into 24 well plate; then incubated at 37C°/ CO₂ for 30 minutes to let the hydrogel to polymerizing. Media was added after the hydrogel containing cells had been polymerized.

5.3 Results

Lyophilized microcapsules in hydrogel:

Lyophilized microcapsules were mixed with freshly prepared type I collagen hydrogel and incubated for 30 minutes at 37°C in order for the hydrogel to polymerize. Rehydration of lyophilized microcapsules were investigated under light microscope to verify that microcapsules were able to rehydrate within the hydrogel and retain their original shape (spherical) Figure 4.1 (B).

Encapsulated cells in hydrogel:

Encapsulated cells were mixed with freshly prepared type I collagen hydrogel and incubated at 37°C for 30 minutes. After polymerization of the hydrogel, we added media on the top of the hydrogel and we incubate it at 37°C and 5% CO₂ as it is shown in Figure 4.2 (B). Live/ dead assay was performed to test encapsulated cells viability within the hydrogel, and it was demonstrated that cells were still preserving their viability in Figure 4.2 (C) where live cells expressed in green.

5.4 Discussion

Hydrogels are natural and synthetic three-dimensional systems with hydrophilic polymer chains which provide ability to hold high content of water. They have broad uses in biomedical research including drug delivery, regenerative medicine, and tissue engineering.^{58,61,149–151} The diversity of hydrogel applications is dependent upon the special traits of hydrogel that spans from biocompatibility, adjustable chemical properties, ability to mimic extracellular matrix, and serve as growth medium¹⁵¹. As an

attempt to further improve A-PLO microcapsules for therapeutic applications, we utilized the lyophilized microcapsules and encapsulated cells to be mixed with type I collagen hydrogel. Our study shows that lyophilized microcapsules have the ability to rehydrate after being mixed with the hydrogel during its polymerization. The lyophilized microcapsules were empty; however we are demonstrating the effectiveness of the system as a tool for application in which the microcapsules can be filled with different therapeutic materials. Moreover, we also demonstrated the ability of the encapsulated ARPE-19 cells to be loaded into type I collagen hydrogels in which it can be used for regenerative medicine and as a delivery system.




Figure 5.1 Lyophilized microcapsules and their rehydration after mix with collagen hydrogel.

(A) Microcapsules appear shrunk and dried after lyophilization. Lyophilized microcapsules rehydrated and returned their spherical shape again after mix with type I collagen hydrogel. Scale bars = 50 microns.




Figure 5.2 Viability of encapsulated ARPE-19 cells embedded within type I collagen hydrogel.

(A) Encapsulated ARPE-19 cells in DMEM media. (B) Encapsulated cells embedded in the hydrogel gel and incubated with media. (C) Encapsulated cells within the hydrogel were stained for their viability via live/dead assay. The Green was an indication of cell viability while the red indicated the damaged cells. Scale bars= 100 microns.

CHAPTER VI

SUMMARY AND FUTURE WORK

Summary

Electrospray microencapsulation has been used in our lab previously to show enhanced wound healing in a rodent model. The previous work concentrated on the encapsulation of a small peptide known as α CT1⁸⁵; in addition, we have had success in encapsulating different constituents such as proteins, antimicrobial agents, and even cells. In this work, I was able to show several enhancements to the original encapsulation technique for both wound healing and cell therapy. I was able to lyophilize the alginate-PLO microcapsules without damaging their morphology following rehydration with the addition of DI water or Tyrodes buffer. Interestingly the microcapsules regain their spherical shape with some surface irregularity. I was also able to show that addition of lyophilized microcapsules to a gelling collagen matrix also showed the ability to hydrate back into their original spherical shape. To investigate the process for cell based therapies, I was able to encapsulate various cell types using the same method of encapsulation by tweaking the voltages and flow rates for optimum cell viability, and showed the ability of the cells to survive the voltage applied during microencapsulation technique. Encapsulated cells (ARPE-19, genetically engineered ARPE-19, and skMDC) were tested for viability after encapsulation using live/ dead assay, and the cells types

were shown to be viable within the microcapsules. We took this to an in vivo model of age related macular degeneration (AMD) and showed that addition of genetically modified ARPE-19 cells expressing the protein CR2-fh was able to ameliorate the symptoms of AMD in a mouse model. To determine whether the encapsulation process had interfered with the cells proliferative ability, we tested the cells when dissolved from the capsules and demonstrated their ability to continue to proliferate in culture and were passaged multiple times thereafter. Finally, we showed that the skMDCs retained several key markers, Pax7, desmin and MyoD following dissolving and further culturing. Indicating that the encapsulation process is not affecting the cells proliferative capabilities nor losing their inherent genetic profile.

We also demonstrated our ability to cryopreserve the microencapsulated cells for a period that resembles long term storage for future experimental use, and showed their viability after thawing and culturing in media. We froze the encapsulated cells and stored them at both -80C and also liquid nitrogen. Cells frozen in both conditions showed the ability to regain their growth potential. Finally, encapsulated cells were incorporated successfully within type I collagen hydrogels where the cells preserved their viability while cultured within this system which can be further utilized for tissue engineering and sustain release delivery of therapeutics.

Future Work

Presented here is a promising technique that can be tuned for its utilization according to each approach discussed in this study. Further investigations are needed for the effect of lyophilization on release profiles of materials such as α CT1, and BSA

loaded A-PLO microcapsules; a complete and comprehensive analysis of loaded lyophilized microcapsules for their sustained release and therapeutic effect on wound healing needs further investigation. In the future encapsulation of multiple cell types in the capsules is planned. It's believed that the cells interact in vivo could in fact be encapsulated to mimic their in vivo interactions. We would also begin examining the ability to further coat the microcapsules with antibodies to further target the addition of the microcapsules within the body to certain tissues or cells. Additionally, a single report exists of the ability to lyophilize microencapsulated cells. We plan to further our initial work to determine if this is another viable option of our system. Finally, we plan to generate an animal model for skeletal muscle atrophy and/or degeneration and use our encapsulated skMDCs to fully evaluate the therapeutic potentials of encapsulating skMDC cells in these types of muscle diseases. Thus providing us a true bench top to bedside application in the future.

REFERENCES

1. Allen TM, Cullis PR. Drug Delivery Systems: Entering the Mainstream. *Science*. 2004;303(5665):1818-1822. doi:10.1126/science.1095833
2. Tønnesen HH, Karlsen J. Alginate in Drug Delivery Systems. *Drug Dev Ind Pharm*. 2002;28(6):621-630. doi:10.1081/DDC-120003853
3. Enayati M, Ahmad Z, Stride E, Edirisinghe M. Preparation of Polymeric Carriers for Drug Delivery with Different Shape and Size Using an Electric Jet. *Curr Pharm Biotechnol*. 2009;10(6):600-608. doi:10.2174/138920109789069323
4. Gómez Gaete C, Tsapis N, Silva L, Bourgaux C, Fattal E. Morphology, structure and supramolecular organization of hybrid 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine–hyaluronic acid microparticles prepared by spray drying. *Eur J Pharm Sci*. 2008;34(1):12-21. doi:10.1016/j.ejps.2008.02.003
5. Yang Y-Y, Chung T-S, Ping Ng N. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. *Biomaterials*. 2001;22(3):231-241. doi:10.1016/S0142-9612(00)00178-2
6. Vilos C, Velasquez LA. Therapeutic Strategies Based on Polymeric Microparticles. *BioMed Res Int*. 2012;2012:e672760. doi:10.1155/2012/672760

7. Xu Y, Skotak M, Hanna M. Electrospray encapsulation of water-soluble protein with polylactide. I. Effects of formulations and process on morphology and particle size. *J Microencapsul.* 2006;23(1):69-78.
8. Casper CL, Yamaguchi N, Kiick KL, Rabolt JF. Functionalizing Electrospun Fibers with Biologically Relevant Macromolecules. *Biomacromolecules.* 2005;6(4):1998-2007. doi:10.1021/bm050007e
9. Chakraborty S, Liao I-C, Adler A, Leong KW. Electrohydrodynamics: A facile technique to fabricate drug delivery systems. *Adv Drug Deliv Rev.* 2009;61(12):1043-1054. doi:10.1016/j.addr.2009.07.013
10. Zhang W, He X. Encapsulation of living cells in small (approximately 100 microm) alginate microcapsules by electrostatic spraying: a parametric study. *J Biomech Eng.* 2009;131(7):074515. doi:10.1115/1.3153326
11. Chew SY, Wen J, Yim EKF, Leong KW. Sustained release of proteins from electrospun biodegradable fibers. *Biomacromolecules.* 2005;6(4):2017-2024. doi:10.1021/bm0501149
12. Takka S, Gürel A. Evaluation of Chitosan/Alginate Beads Using Experimental Design: Formulation and In Vitro Characterization. *AAPS PharmSciTech.* 2010;11(1):460-466. doi:10.1208/s12249-010-9406-z
13. Jaworek A, Krupa A. CLASSIFICATION OF THE MODES OF EHD SPRAYING. *J Aerosol Sci.* 1999;30(7):873-893. doi:10.1016/S0021-8502(98)00787-3

14. Jaworek A, Krupa A. Jet and drops formation in electrohydrodynamic spraying of liquids. A systematic approach. *Exp Fluids*. 1999;27(1):43-52. doi:10.1007/s003480050327
15. Paine MD, Alexander MS, Stark JPW. Nozzle and liquid effects on the spray modes in nanoelectrospray. *J Colloid Interface Sci*. 2007;305(1):111-123. doi:10.1016/j.jcis.2006.09.031
16. Jain D, Bar-Shalom D. Alginate drug delivery systems: application in context of pharmaceutical and biomedical research. *Drug Dev Ind Pharm*. 2014;40(12):1576-1584. doi:10.3109/03639045.2014.917657
17. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for Drug Delivery Systems. *Annu Rev Chem Biomol Eng*. 2010;1:149-173. doi:10.1146/annurev-chembioeng-073009-100847
18. Gaspar DPR. Novel strategy to produce a drug delivery system for skin regeneration. *Uma nova estratégia para produzir um dispositivo para entrega de fármacos que será usado na regeneração da pele*. June 2012. <http://ubithesis.ubi.pt/handle/10400.6/11118>. Accessed September 4, 2014.
19. Huang S, Fu X. Naturally derived materials-based cell and drug delivery systems in skin regeneration. *J Controlled Release*. 2010;142(2):149-159. doi:10.1016/j.jconrel.2009.10.018
20. Nograles N, Abdullah S, Shamsudin MN, Billa N, Rosli R. Formation and characterization of pDNA-loaded alginate microspheres for oral administration in mice. *J Biosci Bioeng*. 2012;113(2):133-140. doi:10.1016/j.jbiosc.2011.10.003

21. Orive G, Tam SK, Pedraz JL, Hallé J-P. Biocompatibility of alginate–poly-l-lysine microcapsules for cell therapy. *Biomaterials*. 2006;27(20):3691-3700. doi:10.1016/j.biomaterials.2006.02.048
22. Zhang Y, Wei W, Lv P, Wang L, Ma G. Preparation and evaluation of alginate–chitosan microspheres for oral delivery of insulin. *Eur J Pharm Biopharm*. 2011;77(1):11-19. doi:10.1016/j.ejpb.2010.09.016
23. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. *Prog Polym Sci*. 2012;37(1):106-126. doi:10.1016/j.progpolymsci.2011.06.003
24. Paul A, Shum-Tim D, Prakash S. Investigation on PEG Integrated Alginate–Chitosan Microcapsules for Myocardial Therapy Using Marrow Stem Cells Genetically Modified by Recombinant Baculovirus. *Cardiovasc Eng Technol*. 2010;1(2):154-164. doi:10.1007/s13239-010-0017-3
25. Zhang W-J, Li B-G, Zhang C, Xie X-H, Tang T-T. Biocompatibility and membrane strength of C3H10T1/2 cell-loaded alginate-based microcapsules. *Cytotherapy*. 2008;10(1):90-97. doi:10.1080/14653240701762372
26. Qian X-M, Huang W-R, Lou P-H. A Method for Optimizing Technical Parameters of the Vacuum Freeze-Drying Process. *Metoda Za Optim Teh Parametara Liofilizacije*. 2014;63(7/8):265-268. doi:10.15255/KUI.2013.011
27. Siew A. Freeze drying protein formulations: a closer look at the common challenges and key considerations when developing a freeze-drying cycle for protein pharmaceuticals. *Pharm Technol Eur*. 2014;(5):20.

28. Temmerman M-L, Rejman J, Grooten J, et al. Lyophilization of Protein-Loaded Polyelectrolyte Microcapsules. *Pharm Res.* 2011;28(7):1765-1773. doi:10.1007/s11095-011-0411-z
29. Wang W. Lyophilization and development of solid protein pharmaceuticals. *Int J Pharm.* 2000;203(1–2):1-60. doi:10.1016/S0378-5173(00)00423-3
30. Dufresne J, Hoang T, Ajambo J, Florentinus-Mefailoski A, Bowden P, Marshall J. Freeze-dried plasma proteins are stable at room temperature for at least 1 year. *Clin Proteomics.* 2017;14:35. doi:10.1186/s12014-017-9170-0
31. Flood A, Estrada M, McAdams D, Ji Y, Chen D. Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation. *PloS One.* 2016;11(11):e0164692. doi:10.1371/journal.pone.0164692
32. Wolkers WF, Walker NJ, Tablin F, Crowe JH. Human Platelets Loaded with Trehalose Survive Freeze-Drying. *Cryobiology.* 2001;42(2):79-87. doi:10.1006/cryo.2001.2306
33. Wakayama T, Yanagimachi R. Development of normal mice from oocytes injected with freeze-dried spermatozoa. *Nat Biotechnol.* 1998;16(7):639-641. doi:10.1038/nbt0798-639
34. Hirabayashi M, Kato M, Ito J, Hochi S. Viable rat offspring derived from oocytes intracytoplasmically injected with freeze-dried sperm heads. *Zygote Camb Engl.* 2005;13(1):79-85.
35. Hsu CC, Ward CA, Pearlman R, Nguyen HM, Yeung DA, Curley JG. Determining the optimum residual moisture in lyophilized protein pharmaceuticals. *Dev Biol Stand.* 1992;74:255-270; discussion 271.

36. Alkeev N, Averin S, von Gratowski S. New Method for Monitoring the Process of Freeze Drying of Biological Materials. *AAPS PharmSciTech*. 2015;16(6):1474-1479. doi:10.1208/s12249-015-0341-x
37. Pikal MJ, Dellerman K, Roy ML. Formulation and stability of freeze-dried proteins: effects of moisture and oxygen on the stability of freeze-dried formulations of human growth hormone. *Dev Biol Stand*. 1992;74:21-37; discussion 37-38.
38. Wikström J, Elomaa M, Nevala L, et al. Viability of freeze dried microencapsulated human retinal pigment epithelial cells. *Eur J Pharm Sci*. 2012;47(2):520-526. doi:10.1016/j.ejps.2012.06.014
39. Wikström J, Elomaa M, Nevala L, et al. Viability of freeze dried microencapsulated human retinal pigment epithelial cells. *Eur J Pharm Sci*. 2012;47(2):520-526. doi:10.1016/j.ejps.2012.06.014
40. Rudolph AS, Crowe JH. Membrane stabilization during freezing: the role of two natural cryoprotectants, trehalose and proline. *Cryobiology*. 1985;22(4):367-377.
41. Crowe JH, Tablin F, Wolters WF, Gousset K, Tsvetkova NM, Ricker J. Stabilization of membranes in human platelets freeze-dried with trehalose. *Chem Phys Lipids*. 2003;122(1-2):41-52.
42. Elbein AD, Pan YT, Pastuszak I, Carroll D. New insights on trehalose: a multifunctional molecule. *Glycobiology*. 2003;13(4):17R-27R. doi:10.1093/glycob/cwg047

43. Crowe LM, Mouradian R, Crowe JH, Jackson SA, Womersley C. Effects of carbohydrates on membrane stability at low water activities. *Biochim Biophys Acta*. 1984;769(1):141-150.
44. Sun WQ, Leopold AC, Crowe LM, Crowe JH. Stability of dry liposomes in sugar glasses. *Biophys J*. 1996;70(4):1769-1776. doi:10.1016/S0006-3495(96)79740-0
45. Gordon SL, Oppenheimer SR, Mackay AM, Brunnabend J, Puhlev I, Levine F. Recovery of human mesenchymal stem cells following dehydration and rehydration. *Cryobiology*. 2001;43(2):182-187. doi:10.1006/cryo.2001.2361
46. Matsuo T. Trehalose protects corneal epithelial cells from death by drying. *Br J Ophthalmol*. 2001;85(5):610-612.
47. Xiao H-H, Hua T-C, Li J, et al. Freeze-drying of mononuclear cells and whole blood of human cord blood. *Cryo Letters*. 2004;25(2):111-120.
48. Murua A, Portero A, Orive G, Hernández RM, de Castro M, Pedraz JL. Cell microencapsulation technology: Towards clinical application. *J Controlled Release*. 2008;132(2):76-83. doi:10.1016/j.jconrel.2008.08.010
49. Calafiore R. Microencapsulation for cell therapy of type 1 diabetes mellitus: The interplay between common beliefs, prejudices and real progress. *J Diabetes Investig*. 2018;9(2):231-233. doi:10.1111/jdi.12788
50. Gryshkov O, Pogozykh D, Hofmann N, Pogozykh O, Mueller T, Glasmacher B. Encapsulating Non-Human Primate Multipotent Stromal Cells in Alginate via High Voltage for Cell-Based Therapies and Cryopreservation. *PLoS ONE*. 2014;9(9). doi:10.1371/journal.pone.0107911

51. Gryshkov O, Pogozhykh D, Zernetsch H, Hofmann N, Mueller T, Glasmacher B. Process engineering of high voltage alginate encapsulation of mesenchymal stem cells. *Mater Sci Eng C*. 2014;36:77-83. doi:10.1016/j.msec.2013.11.048
52. Montanucci P, Alunno A, Basta G, et al. Restoration of t cell subtypes of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells: An in vitro study. *Clin Immunol Orlando Fla*. 2016;163:34-41. doi:10.1016/j.clim.2015.12.002
53. Annabi N, Nichol JW, Zhong X, et al. Controlling the porosity and microarchitecture of hydrogels for tissue engineering. *Tissue Eng Part B Rev*. 2010;16(4):371-383. doi:10.1089/ten.TEB.2009.0639
54. Annabi Nasim, Tamayol Ali, Uquillas Jorge Alfredo, et al. 25th Anniversary Article: Rational Design and Applications of Hydrogels in Regenerative Medicine. *Adv Mater*. 2013;26(1):85-124. doi:10.1002/adma.201303233
55. Yao X, Liu Y, Gao J, et al. Nitric oxide releasing hydrogel enhances the therapeutic efficacy of mesenchymal stem cells for myocardial infarction. *Biomaterials*. 2015;60:130-140. doi:10.1016/j.biomaterials.2015.04.046
56. Chen S, Nakamoto T, Kawazoe N, Chen G. Engineering multi-layered skeletal muscle tissue by using 3D microgrooved collagen scaffolds. *Biomaterials*. 2015;73:23-31. doi:10.1016/j.biomaterials.2015.09.010
57. Gibas I, Janik H. REVIEW: SYNTHETIC POLYMER HYDROGELS FOR BIOMEDICAL APPLICATIONS. :9.

58. Tan H, Ramirez CM, Miljkovic N, Li H, Rubin JP, Marra KG. Thermosensitive injectable hyaluronic acid hydrogel for adipose tissue engineering. *Biomaterials*. 2009;30(36):6844-6853. doi:10.1016/j.biomaterials.2009.08.058
59. Bae KH, Lee F, Xu K, et al. Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs. *Biomaterials*. 2015;63:146-157. doi:10.1016/j.biomaterials.2015.06.008
60. Keskar V, Marion NW, Mao JJ, Gemeinhart RA. In vitro evaluation of macroporous hydrogels to facilitate stem cell infiltration, growth, and mineralization. *Tissue Eng Part A*. 2009;15(7):1695-1707. doi:10.1089/ten.tea.2008.0238
61. Kroupová J, Horák D, Pacherník J, Dvorák P, Slouf M. Functional polymer hydrogels for embryonic stem cell support. *J Biomed Mater Res B Appl Biomater*. 2006;76(2):315-325. doi:10.1002/jbm.b.30366
62. Cornwell KG, Landsman A, James KS. Extracellular matrix biomaterials for soft tissue repair. *Clin Podiatr Med Surg*. 2009;26(4):507-523. doi:10.1016/j.cpm.2009.08.001
63. Lee S, Valmikinathan CM, Byun J, et al. Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes. *Biomaterials*. 2015;63:158-167. doi:10.1016/j.biomaterials.2015.06.009
64. Murphy WL, McDevitt TC, Engler AJ. Materials as stem cell regulators. *Nat Mater*. 2014;13(6):547-557. doi:10.1038/nmat3937

65. Silva R, Fabry B, Boccaccini AR. Fibrous protein-based hydrogels for cell encapsulation. *Biomaterials*. 2014;35(25):6727-6738. doi:10.1016/j.biomaterials.2014.04.078
66. Cai Lei, Dewi Ruby E., Heilshorn Sarah C. Injectable Hydrogels with In Situ Double Network Formation Enhance Retention of Transplanted Stem Cells. *Adv Funct Mater*. 2015;25(9):1344-1351. doi:10.1002/adfm.201403631
67. Tsou Y-H, Khoneisser J, Huang P-C, Xu X. Hydrogel as a bioactive material to regulate stem cell fate. *Bioact Mater*. 2016;1(1):39-55. doi:10.1016/j.bioactmat.2016.05.001
68. Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and applications. *Biomaterials*. 2003;24(24):4337-4351. doi:10.1016/S0142-9612(03)00340-5
69. Parmar PA, Chow LW, St-Pierre J-P, et al. Collagen-mimetic peptide-modifiable hydrogels for articular cartilage regeneration. *Biomaterials*. 2015;54:213-225. doi:10.1016/j.biomaterials.2015.02.079
70. Szot CS, Buchanan CF, Freeman JW, Rylander MN. 3D in vitro bioengineered tumors based on collagen I hydrogels. *Biomaterials*. 2011;32(31):7905-7912. doi:10.1016/j.biomaterials.2011.07.001
71. Rafat M, Xeroudaki M, Koulikovska M, et al. Composite core-and-skirt collagen hydrogels with differential degradation for corneal therapeutic applications. *Biomaterials*. 2016;83:142-155. doi:10.1016/j.biomaterials.2016.01.004

72. O'Connor SM, Stenger DA, Shaffer KM, Ma W. Survival and neurite outgrowth of rat cortical neurons in three-dimensional agarose and collagen gel matrices. *Neurosci Lett*. 2001;304(3):189-193.
73. Joosten E a. J, Veldhuis WB, Hamers FPT. Collagen containing neonatal astrocytes stimulates regrowth of injured fibers and promotes modest locomotor recovery after spinal cord injury. *J Neurosci Res*. 2004;77(1):127-142. doi:10.1002/jnr.20088
74. Hsiao TW, Tresco PA, Hlady V. Astrocytes alignment and reactivity on collagen hydrogels patterned with ECM proteins. *Biomaterials*. 2015;39:124-130. doi:10.1016/j.biomaterials.2014.10.062
75. Dingal PCDP, Bradshaw AM, Cho S, et al. Fractal heterogeneity in minimal matrix models of scars modulates stiff-niche stem-cell responses via nuclear exit of a mechanorepressor. *Nat Mater*. 2015;14(9):951-960. doi:10.1038/nmat4350
76. Antoine EE, Vlachos PP, Rylander MN. Review of Collagen I Hydrogels for Bioengineered Tissue Microenvironments: Characterization of Mechanics, Structure, and Transport. *Tissue Eng Part B Rev*. 2014;20(6):683-696. doi:10.1089/ten.teb.2014.0086
77. Kayser O, Lemke A, Hernández-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. *Curr Pharm Biotechnol*. 2005;6(1):3-5.
78. Kim KK, Pack DW. Microspheres for Drug Delivery. In: Ferrari M, Lee AP, Lee LJ, eds. *BioMEMS and Biomedical Nanotechnology*. Springer US; 2006:19-50.

http://link.springer.com/chapter/10.1007/978-0-387-25842-3_2. Accessed September 10, 2014.

79. Darrabie MD, Kendall WF, Opara EC. Characteristics of Poly-L-Ornithine-coated alginate microcapsules. *Biomaterials*. 2005;26(34):6846-6852. doi:10.1016/j.biomaterials.2005.05.009
80. Moore K, Ghatnekar G, Gourdie RG, Potts JD. Impact of the Controlled Release of a Connexin 43 Peptide on Corneal Wound Closure in an STZ Model of Type I Diabetes. *PLOS ONE*. 2014;9(1):e86570. doi:10.1371/journal.pone.0086570
81. Rezende YRRS, Nogueira JP, Narain N. Microencapsulation of extracts of bioactive compounds obtained from acerola (*Malpighia emarginata* DC) pulp and residue by spray and freeze drying: Chemical, morphological and chemometric characterization. *Food Chem*. 2018;254:281-291. doi:10.1016/j.foodchem.2018.02.026
82. Boge L, Västberg A, Umerska A, et al. Freeze-dried and re-hydrated liquid crystalline nanoparticles stabilized with disaccharides for drug-delivery of the plectasin derivative AP114 antimicrobial peptide. *J Colloid Interface Sci*. 2018;522:126-135. doi:10.1016/j.jcis.2018.03.062
83. Varshosaz J, Ghaffari S, Khoshayand MR, Atyabi F, Dehkordi AJ, Kobarfard F. Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design. *Pharm Dev Technol*. 2012;17(2):187-194. doi:10.3109/10837450.2010.529149

84. Horn J, Schanda J, Friess W. Impact of fast and conservative freeze-drying on product quality of protein-mannitol-sucrose-glycerol lyophilizates. *Eur J Pharm Biopharm.* 2018;127:342-354. doi:10.1016/j.ejpb.2018.03.003
85. Moore K, Amos J, Davis J, Gourdie R, Potts JD. Characterization of polymeric microcapsules containing a low molecular weight peptide for controlled release. *Microsc Microanal Off J Microsc Soc Am Microbeam Anal Soc Microsc Soc Can.* 2013;19(1):213-226. doi:10.1017/S143192761201389X
86. Xu Y, Hanna MA. Electrosprayed bovine serum albumin-loaded tripolyphosphate cross-linked chitosan capsules: synthesis and characterization. *J Microencapsul.* 2007;24(2):143-151.
87. Rey L, May JC, eds. *Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products*. 2nd ed., rev. and expanded. New York: Marcel Dekker; 2004. <http://library.sc.edu/catalog/offcampus.html?url=http://www.tandfebooks.com/isbn/978-0-8247-4868-5>. Accessed April 1, 2018.
88. Chang L (Lucy), Pikal MJ. Mechanisms of protein stabilization in the solid state. *J Pharm Sci.* 2009;98(9):2886-2908. doi:10.1002/jps.21825
89. Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV. Production and Evaluation of Dry Alginate-Chitosan Microcapsules as an Enteric Delivery Vehicle for Probiotic Bacteria. *Biomacromolecules.* 2011;12(7):2834-2840. doi:10.1021/bm200576h
90. Gonzalez-Pujana A, Santos E, Orive G, Pedraz JL, Hernandez RM. Cell microencapsulation technology: Current vision of its therapeutic potential through

- the administration routes. *J Drug Deliv Sci Technol.* 2017;42:49-62.
doi:10.1016/j.jddst.2017.03.028
91. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. *Science.* 1980;210(4472):908-910.
 92. Santos E, Pedraz JL, Hernández RM, Orive G. Therapeutic cell encapsulation: Ten steps towards clinical translation. *J Controlled Release.* 2013;170(1):1-14.
doi:10.1016/j.jconrel.2013.04.015
 93. Annamalai B, Parsons N, Belhaj M, Brandon C, Potts J, Rohrer B. Encapsulated Cell Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal Neovascularization in a Mouse Model. *Transl Vis Sci Technol.* 2018;7(2):3-3.
doi:10.1167/tvst.7.2.3
 94. Balyura M, Gelfgat E, Ehrhart-Bornstein M, et al. Transplantation of bovine adrenocortical cells encapsulated in alginate. *Proc Natl Acad Sci U S A.* 2015;112(8):2527-2532. doi:10.1073/pnas.1500242112
 95. Belhaj M, Menon V, Rohrer B, Potts J. Alginate Microcapsule Technology and Impacts on Cell Therapy Development. *Microsc Microanal.* 2017;23(S1):1214-1215. doi:10.1017/S1431927617006730
 96. Bhujbal SV, de Vos P, Niclou SP. Drug and cell encapsulation: Alternative delivery options for the treatment of malignant brain tumors. *Adv Drug Deliv Rev.* 2014;67-68:142-153. doi:10.1016/j.addr.2014.01.010
 97. Hidalgo San Jose L, Stephens P, Song B, Barrow D. Microfluidic Encapsulation Supports Stem Cell Viability, Proliferation, and Neuronal Differentiation. *Tissue Eng Part C Methods.* 2017;24(3):158-170. doi:10.1089/ten.tec.2017.0368

98. Hillberg AL, Oudshoorn M, Lam JBB, Kathirgamanathan K. Encapsulation of porcine pancreatic islets within an immunoprotective capsule comprising methacrylated glycol chitosan and alginate. *J Biomed Mater Res B Appl Biomater*. 2015;103(3):503-518. doi:10.1002/jbm.b.33185
99. Maguire T, Novik E, Schloss R, Yarmush M. Alginate-PLL microencapsulation: Effect on the differentiation of embryonic stem cells into hepatocytes. *Biotechnol Bioeng*. 2006;93(3):581-591. doi:10.1002/bit.20748
100. Perez RA, Kim M, Kim T-H, et al. Utilizing Core–Shell Fibrous Collagen–Alginate Hydrogel Cell Delivery System for Bone Tissue Engineering. *Tissue Eng Part A*. 2014;20(1-2):103-114. doi:10.1089/ten.tea.2013.0198
101. Pravdyuk AI, Petrenko YA, Fuller BJ, Petrenko AY. Cryopreservation of alginate encapsulated mesenchymal stromal cells. *Cryobiology*. 2013;66(3):215-222. doi:10.1016/j.cryobiol.2013.02.002
102. Richardson T, Kumta PN, Banerjee I. Alginate Encapsulation of Human Embryonic Stem Cells to Enhance Directed Differentiation to Pancreatic Islet-Like Cells. *Tissue Eng Part A*. 2014;20(23-24):3198-3211. doi:10.1089/ten.tea.2013.0659
103. Swioklo S, Constantinescu A, Connon CJ. Alginate-Encapsulation for the Improved Hypothermic Preservation of Human Adipose-Derived Stem Cells. *Stem Cells Transl Med*. 2016;5(3):339-349. doi:10.5966/sctm.2015-0131
104. Wang N, Adams G, Buttery L, Falcone FH, Stolnik S. Alginate encapsulation technology supports embryonic stem cells differentiation into insulin-producing cells. *J Biotechnol*. 2009;144(4):304-312. doi:10.1016/j.jbiotec.2009.08.008

105. Rohrer B, Long Q, Coughlin B, et al. A Targeted Inhibitor of the Alternative Complement Pathway Reduces Angiogenesis in a Mouse Model of Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci.* 2009;50(7):3056-3064. doi:10.1167/iovs.08-2222
106. Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. *J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther.* 2012;28(4):402-409. doi:10.1089/jop.2011.0212
107. Alawieh A, Elvington A, Zhu H, et al. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. *J Neuroinflammation.* 2015;12:247. doi:10.1186/s12974-015-0464-8
108. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A Novel Targeted Inhibitor of the Alternative Pathway of Complement and Its Therapeutic Application in Ischemia/Reperfusion Injury. *J Immunol Baltim Md 1950.* 2008;181(11):8068-8076.
109. Sekine H, Kinser TTH, Qiao F, et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. *Arthritis Rheum.* 2011;63(4):1076-1085. doi:10.1002/art.30222
110. Owens J, Moreira K, Bain G. Characterization of primary human skeletal muscle cells from multiple commercial sources. *In Vitro Cell Dev Biol Anim.* 2013;49(9):695-705. doi:10.1007/s11626-013-9655-8

111. Shaw PX, Stiles T, Douglas C, et al. Oxidative stress, innate immunity, and age-related macular degeneration. *AIMS Mol Sci.* 2016;3(2):196-221. doi:10.3934/molsci.2016.2.196
112. Bulgu Y, Cetin GO, Caner V, Cetin EN, Yaylali V, Yildirim C. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration in a Turkish population. *Int J Ophthalmol.* 2014;7(5):773-777. doi:10.3980/j.issn.2222-3959.2014.06
113. Courtenay MD, Cade WH, Schwartz SG, et al. Set-Based Joint Test of Interaction Between SNPs in the VEGF Pathway and Exogenous Estrogen Finds Association With Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci.* 2014;55(8):4873-4879. doi:10.1167/iovs.14-14494
114. Gupta D, Gupta V, Singh V, et al. Vascular endothelial growth factor gene polymorphisms and association with age related macular degeneration in Indian patients. *Meta Gene.* 2016;9:249-253. doi:10.1016/j.mgene.2016.07.011
115. Lazzeri S, Orlandi P, Figus M, et al. The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. *ScientificWorldJournal.* 2012;2012:420190. doi:10.1100/2012/420190
116. Fauser S, Lambrou GN. Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration. *Surv Ophthalmol.* 2015;60(2):138-152. doi:10.1016/j.survophthal.2014.11.002
117. Hagstrom SA, Ying G, Pauer GJT, et al. VEGFA and VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy: Comparison of Age-Related Macular Degeneration Treatments Trials

- (CATT). *JAMA Ophthalmol.* 2014;132(5):521-527.
doi:10.1001/jamaophthalmol.2014.109
118. Tan PL, Bowes Rickman C, Katsanis N. AMD and the alternative complement pathway: genetics and functional implications. *Hum Genomics.* 2016;10.
doi:10.1186/s40246-016-0079-x
 119. Müller-Eberhard HJ. Molecular Organization and Function of the Complement System. *Annu Rev Biochem.* 1988;57(1):321-347.
doi:10.1146/annurev.bi.57.070188.001541
 120. Joseph K, Kulik L, Coughlin B, et al. Oxidative Stress Sensitizes Retinal Pigmented Epithelial (RPE) Cells to Complement-mediated Injury in a Natural Antibody-, Lectin Pathway-, and Phospholipid Epitope-dependent Manner. *J Biol Chem.* 2013;288(18):12753-12765. doi:10.1074/jbc.M112.421891
 121. Thurman JM, Renner B, Kunchithapautham K, et al. Oxidative Stress Renders Retinal Pigment Epithelial Cells Susceptible to Complement-mediated Injury. *J Biol Chem.* 2009;284(25):16939-16947. doi:10.1074/jbc.M808166200
 122. Bandyopadhyay M, Rohrer B. Matrix Metalloproteinase Activity Creates Pro-Angiogenic Environment in Primary Human Retinal Pigment Epithelial Cells Exposed to Complement. *Invest Ophthalmol Vis Sci.* 2012;53(4):1953-1961.
doi:10.1167/iovs.11-8638
 123. Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM. Systemic Human CR2-Targeted Complement Alternative Pathway Inhibitor Ameliorates Mouse Laser-Induced Choroidal Neovascularization. *J Ocul Pharmacol Ther.* 2012;28(4):402-409. doi:10.1089/jop.2011.0212

124. Rohrer B, Long Q, Coughlin B, et al. A Targeted Inhibitor of the Alternative Complement Pathway Reduces Angiogenesis in a Mouse Model of Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2009;50(7):3056-3064. doi:10.1167/iovs.08-2222
125. Woodell A, Jones BW, Williamson T, et al. A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. *Invest Ophthalmol Vis Sci*. 2016;57(4):1728-1737. doi:10.1167/iovs.15-18471
126. Banda NK, Levitt B, Glogowska MJ, et al. Targeted Inhibition of the Complement Alternative Pathway with Complement Receptor 2 and Factor H Attenuates Collagen Antibody-Induced Arthritis in Mice. *J Immunol Baltim Md 1950*. 2009;183(9):5928-5937. doi:10.4049/jimmunol.0901826
127. Sun S, Wang H, Zhao G, et al. Complement Inhibition Alleviates Paraquat-Induced Acute Lung Injury. *Am J Respir Cell Mol Biol*. 2011;45(4):834-842. doi:10.1165/rcmb.2010-0444OC
128. Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. *Adv Exp Med Biol*. 2013;735:137-154.
129. Schnabolk G, Parsons N, Obert E, et al. Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization. *Mol Ther Methods Clin Dev*. 2017;9:1-11. doi:10.1016/j.omtm.2017.11.003

130. Raisler BJ, Sakurai E, Nozaki M, Baffi JZ, Ambati BK, Ambati J. Drusen Complement Components C3a and C5a Promote Choroidal Neovascularization. *Invest Ophthalmol Vis Sci.* 2005;46(13):1214-1214.
131. Coughlin B, Schnabolk G, Joseph K, et al. Connecting the innate and adaptive immune responses in mouse choroidal neovascularization via the anaphylatoxin C5a and $\gamma\delta$ T-cells. *Sci Rep.* 2016;6:23794. doi:10.1038/srep23794
132. Schnabolk G, Coughlin B, Joseph K, et al. Local Production of the Alternative Pathway Component Factor B Is Sufficient to Promote Laser-Induced Choroidal Neovascularization. *Invest Ophthalmol Vis Sci.* 2015;56(3):1850-1863. doi:10.1167/iovs.14-15910
133. Giani A, Thanos A, Roh MI, et al. In Vivo Evaluation of Laser-Induced Choroidal Neovascularization Using Spectral-Domain Optical Coherence Tomography. *Invest Ophthalmol Vis Sci.* 2011;52(6):3880-3887. doi:10.1167/iovs.10-6266
134. Alawieh A, Tomlinson S. Injury site-specific targeting of complement inhibitors for treating stroke. *Immunol Rev.* 2016;274(1):270-280. doi:10.1111/imr.12470
135. Sekine H, Kinser TTH, Qiao F, et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. *Arthritis Rheum.* 2011;63(4):1076-1085. doi:10.1002/art.30222
136. Wong FSY, Tsang KK, Lo ACY. Delivery of therapeutics to posterior eye segment: cell-encapsulating systems. *Neural Regen Res.* 2017;12(4):576-577. doi:10.4103/1673-5374.205093

137. BIRCH DG, WELEBER RG, DUNCAN JL, JAFFE GJ, TAO W. Randomized Trial of Ciliary Neurotrophic Factor Delivered by Encapsulated Cell Intraocular Implants for Retinitis Pigmentosa. *Am J Ophthalmol.* 2013;156(2):283-292.e1. doi:10.1016/j.ajo.2013.03.021
138. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. *Proc Natl Acad Sci.* 2011;108(15):6241-6245. doi:10.1073/pnas.1018987108
139. An E, Gordish-Dressman H, Hathout Y. Effect of TNF- α on human ARPE-19-secreted proteins. *Mol Vis.* 2008;14:2292-2303.
140. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement - a key system for immune surveillance and homeostasis. *Nat Immunol.* 2010;11(9):785-797. doi:10.1038/ni.1923
141. Liu MM, Tuo J, Chan C-C. Republished review: Gene therapy for ocular diseases. *Postgrad Med J.* 2011;87(1029):487-495. doi:10.1136/pgmj.2009.174912rep
142. Naidoo J, Young D. Gene Regulation Systems for Gene Therapy Applications in the Central Nervous System. *Neurology Research International.* doi:10.1155/2012/595410
143. Nicodemus GD, Bryant SJ. Cell Encapsulation in Biodegradable Hydrogels for Tissue Engineering Applications. *Tissue Eng Part B Rev.* 2008;14(2):149-165. doi:10.1089/ten.teb.2007.0332

144. Gribova V, Crouzier T, Picart C. A material's point of view on recent developments of polymeric biomaterials: control of mechanical and biochemical properties. *J Mater Chem*. 2011;21(38):14354-14366. doi:10.1039/C1JM11372K
145. Levy-Mishali M, Zoldan J, Levenberg S. Effect of Scaffold Stiffness on Myoblast Differentiation. *Tissue Eng Part A*. 2008;15(4):935-944. doi:10.1089/ten.tea.2008.0111
146. Ramanujan S, Pluen A, McKee TD, Brown EB, Boucher Y, Jain RK. Diffusion and Convection in Collagen Gels: Implications for Transport in the Tumor Interstitium. *Biophys J*. 2002;83(3):1650-1660. doi:10.1016/S0006-3495(02)73933-7
147. Ulrich TA, Jain A, Tanner K, MacKay JL, Kumar S. Probing cellular mechanobiology in three-dimensional culture with collagen–agarose matrices. *Biomaterials*. 2010;31(7):1875-1884. doi:10.1016/j.biomaterials.2009.10.047
148. Wolf K, Alexander S, Schacht V, et al. Collagen-based cell migration models in vitro and in vivo. *Semin Cell Dev Biol*. 2009;20(8):931-941. doi:10.1016/j.semcdb.2009.08.005
149. Aizawa Y, Leipzig N, Zahir T, Shoichet M. The effect of immobilized platelet derived growth factor AA on neural stem/progenitor cell differentiation on cell-adhesive hydrogels. *Biomaterials*. 2008;29(35):4676-4683. doi:10.1016/j.biomaterials.2008.08.018
150. Bae KH, Lee F, Xu K, et al. Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs. *Biomaterials*. 2015;63:146-157. doi:10.1016/j.biomaterials.2015.06.008

151. Sarker B, Rompf J, Silva R, et al. Alginate-based hydrogels with improved adhesive properties for cell encapsulation. *Int J Biol Macromol*. 2015;78:72-78. doi:10.1016/j.ijbiomac.2015.03.061

APPENDIX A- PERMISSION TO REPRINT

For chapters 2, 3

CAMBRIDGE UNIVERSITY PRESS LICENSE TERMS AND CONDITIONS

This Agreement between Marwa Belhaj ("You") and Cambridge University Press ("Cambridge University Press") consists of your license details and the terms and conditions provided by Cambridge University Press and Copyright Clearance Center.

License Number	4306720199647
License date	Mar 12, 2018
Licensed Content Publisher	Cambridge University Press
Licensed Content Publication	Microscopy and Microanalysis
Licensed Content Title	Alginate Microcapsule Technology and Impacts on Cell Therapy Development
Licensed Content Author	Marwa Belhaj, Vinal Menon, Barbel Rohrer, Jay Potts
Licensed Content Date	Aug 4, 2017
Licensed Content Volume	23
Licensed Content Issue	S1
Start page	1214
End page	1215
Type of Use	Dissertation/Thesis
Requestor type	Author
Portion	Full article
Author of this Cambridge University Press article	Yes
Author / editor of the new work	Yes
Order reference number	
Territory for reuse	North America Only
Title of your thesis / Dissertation	ENHANCEMENTS IN ALGINATE MICROENCAPSULATION TECHNOLOGY & IMPACTS ON CELL THERAPY DEVELOPMENT
Expected completion date	May 2018
Estimated size(pages)	1
Requestor Location	Mrs. Marwa Belhaj 6439 Garners Ferry Rd. Bldg-1, Rm C-36 COLUMBIA, SC 29209

Publisher Tax ID
Billing Type
Billing Address

United States
Attn: Marwa Belhaj
GB823847609
Invoice
Marwa Belhaj
6439 Garners Ferry Rd
Bldg-1, Rm C-36
COLUMBIA, SC 29209
United States
Attn: Marwa Belhaj
0.00 USD

Total

Terms and Conditions

TERMS & CONDITIONS

Cambridge University Press grants the Licensee permission on a nonexclusive non-transferable basis to reproduce, make available or otherwise use the Licensed content 'Content' in the named territory 'Territory' for the purpose listed 'the Use' on Page 1 of this Agreement subject to the following terms and conditions.

1. The License is limited to the permission granted and the Content detailed herein and does not extend to any other permission or content.
2. Cambridge gives no warranty or indemnity in respect of any third-party copyright material included in the Content, for which the Licensee should seek separate permission clearance.
3. The integrity of the Content must be ensured.
4. The License does extend to any edition published specifically for the use of handicapped or reading-impaired individuals.
5. The Licensee shall provide a prominent acknowledgement in the following format: author/s, title of article, name of journal, volume number, issue number, page references, reproduced with permission.

Other terms and conditions:

v1.0

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

For chapters 1

**ELSEVIER LICENSE
TERMS AND CONDITIONS**

Mar 12, 2018

This Agreement between Marwa Belhaj ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	4306711383183
License date	Mar 12, 2018
Licensed Content Publisher	Elsevier
Licensed Content Publication	Advanced Drug Delivery Reviews
Licensed Content Title	Drug and cell encapsulation: Alternative delivery options for the treatment of malignant brain tumors
Licensed Content Author	Swapnil V. Bhujbal,Paul de Vos,Simone P. Niclou
Licensed Content Date	Apr 10, 2014
Licensed Content Volume	67
Licensed Content Issue	n/a
Licensed Content Pages	12
Start Page	142
End Page	153
Type of Use	reuse in a thesis/dissertation
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	1
Format	both print and electronic
Are you the author of this Elsevier article?	No
Will you be translating?	No
Original figure numbers	Fig. 2.
Title of your thesis/dissertation	ENHANCEMENTS IN ALGINATE MICROENCAPSULATION TECHNOLOGY & IMPACTS ON CELL THERAPY DEVELOPMENT
Expected completion date	May 2018
Estimated size (# of pages)	1
Requestor Location	Mrs. Marwa Belhaj 6439 Garners Ferry Rd. Bldg-1, Rm C-36 COLUMBIA, SC 29209 United States
Publisher Tax ID	98-0397604
Total	0.00 USD

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]."

Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may

constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. **Warranties:** Publisher makes no representations or warranties with respect to the licensed material.

10. **Indemnity:** You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. **No Transfer of License:** This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. **No Amendment Except in Writing:** This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. **Objection to Contrary Terms:** Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions.

These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you.

Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world English rights only unless your license was granted for translation rights.

If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal:

All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This

license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu. Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. For journal authors: the following clauses are applicable in addition to the above:

Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
 - via their non-commercial person homepage or blog
 - by updating a preprint in arXiv or RePEc with the accepted manuscript
 - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
 - directly by providing copies to their students or to research collaborators for their personal use
 - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
 - via non-commercial hosting platforms such as their institutional repository
 - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do

- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version.

Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

Gold Open Access Articles: May be shared according to the author selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. Posting to a repository: Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

Elsevier Open Access Terms and Conditions

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

Terms & Conditions applicable to all Open Access articles published with Elsevier:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honor or reputation. If any changes have been made, such changes must be clearly indicated. The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative

Commons user license:

CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at

<http://creativecommons.org/licenses/by/4.0>.

CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at

<http://creativecommons.org/licenses/by-nc-sa/4.0>.

CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at

<http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee. Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

20. Other Conditions:

v1.9

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.